0001193125-22-292028.txt : 20221123 0001193125-22-292028.hdr.sgml : 20221123 20221123161217 ACCESSION NUMBER: 0001193125-22-292028 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20221122 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221123 DATE AS OF CHANGE: 20221123 FILER: COMPANY DATA: COMPANY CONFORMED NAME: scPharmaceuticals Inc. CENTRAL INDEX KEY: 0001604950 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 465184075 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38293 FILM NUMBER: 221416465 BUSINESS ADDRESS: STREET 1: 2400 DISTRICT AVENUE STREET 2: SUITE 310 CITY: BURLINGTON STATE: MA ZIP: 01803 BUSINESS PHONE: 617-517-0730 MAIL ADDRESS: STREET 1: 2400 DISTRICT AVENUE STREET 2: SUITE 310 CITY: BURLINGTON STATE: MA ZIP: 01803 8-K 1 d240360d8k.htm 8-K 8-K
false 0001604950 0001604950 2022-11-22 2022-11-22

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 22, 2022

 

 

scPharmaceuticals Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38293   46-5184075

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

2400 District Avenue, Suite 310

Burlington, Massachusetts 01803

(Address of principal executive offices) (Zip Code)

(617) 517-0730

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common stock, par value $0.0001   SCPH   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 

 


Item 8.01

Other Events.

On November 22, 2022, scPharmaceuticals Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with SVB Securities LLC and Cowen and Company, LLC, as representatives of the several underwriters named in Schedule A thereto (collectively, the “Underwriters”), relating to an underwritten offering of 6,620,000 shares (the “Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), and, in lieu of Common Stock to a certain investor, a pre-funded warrant (the “Pre-funded Warrant”) to purchase 2,905,000 shares of Common Stock (the “Offering”). The closing of the Offering is expected to take place on November 25, 2022. All of the Shares and the Pre-funded Warrant are being sold by the Company. The offering price of the Shares to the public is $5.25 per share, and the offering price of the Pre-funded Warrant to the public is $5.249 per underlying share, which is equal to the price per share of Common Stock being sold in this offering, minus $0.001, which is the Pre-funded Warrant’s exercise price per share. The net proceeds from the Offering are expected to be approximately $46.6 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company does not intend to list the Pre-funded Warrant on Nasdaq or any other nationally recognized securities exchange or trading system.

The Pre-funded Warrant has an exercise price per share of Common Stock equal to $0.001 per share. The exercise price and the number of shares of Common Stock issuable upon exercise of the Pre-funded Warrant is subject to appropriate adjustments in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock. The Pre-funded Warrant is exercisable from the date of issuance by means of a cashless exercise. Under the Pre-funded Warrant, the Company may not effect the exercise of the Pre-funded Warrant, and the holder will not be entitled to exercise any portion of the Pre-funded Warrant that, upon giving effect to such exercise, would result in: (i) the aggregate number of shares of Common Stock beneficially owned by such holder (together with its affiliates) exceeding 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to the exercise; or (ii) the combined voting power of the Company’s securities beneficially owned by such holder (together with its affiliates) exceeding 4.99% of the combined voting power of all of the Company’s securities outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Pre-funded Warrant, which percentage may be changed at the holder’s election to a higher or lower percentage not in excess of 19.99% upon 61 days’ notice to the Company.

In addition, in certain circumstances, upon a fundamental transaction, the holder of the Pre-funded Warrant will be entitled to receive, upon exercise of the Pre-funded Warrant, the kind and amount of securities, cash or other property that such holder would have received had they exercised the Pre-funded Warrant immediately prior to the fundamental transaction; provided, however, that in the event of a fundamental transaction where the consideration consists solely of cash, solely of marketable securities or a combination thereof, the Pre-funded Warrant will be deemed to be exercised in full in a cashless exercise effective immediately prior to and contingent upon the consummation of such fundamental transaction.

The Company intends to use the net proceeds of the Offering to support the commercialization efforts for FUROSCIX, development of its pipeline, working capital and general corporate purposes. Based on the planned use of proceeds, the Company believes that the net proceeds from the Offering and existing cash, cash equivalents, restricted cash and investments will be sufficient to enable it to fund operating expenses, capital expenditure requirements and planned launch activities through at least 2024. This estimate is based on assumptions that may prove to be incorrect, and the Company could utilize available capital resources sooner than expected.

The Offering was made pursuant to a shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission (“SEC”) on March 23, 2021 and declared effective by the SEC on April 29, 2021 (File No. 333-254637). A prospectus supplement relating to the offering has been filed with the SEC.

The representations, warranties and covenants contained in the Underwriting Agreement were made solely for the benefit of the parties thereto and may be subject to limitations agreed upon by the contracting parties. Accordingly, the Underwriting Agreement is incorporated herein by reference only to provide investors with information regarding the terms of the Underwriting Agreement and not to provide investors with any other factual information regarding the Company or its business, and should be read in conjunction with the disclosures in the Company’s periodic reports and other filings with the SEC.


The foregoing descriptions of the Underwriting Agreement and the Pre-funded Warrant are not complete and are qualified in their entireties by reference to the full text of the Underwriting Agreement and the Form of Pre-funded Warrant, copies of which are filed as Exhibits 1.1 and 4.1, respectively, to this report and are incorporated by reference herein.

A copy of the opinion of Latham & Watkins LLP relating to the legality of the issuance and sale of the Shares, the Pre-funded Warrant and the shares of common stock issuable upon exercise of the Pre-funded Warrant is attached as Exhibit 5.1 to this report.

Forward-Looking Statements

This current report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the closing of the Offering, the Company’s intent not to list the Pre-funded Warrant on Nasdaq or any other securities exchange or automated quotation system; anticipated amount of net proceeds from the Offering, the intended use of such proceeds; and the Company’s belief that the net proceeds from the Offering and existing cash, cash equivalents, restricted cash and investments will be sufficient to enable it to fund operating expenses, capital expenditure requirements and planned launch activities through at least 2024. Any forward-looking statements in this current report are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that amount of and use of net proceeds from the Offering may differ from the Company’s current expectations; results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive reviews of the data, and as more patient data become available, the risk that results of a clinical study are subject to interpretation and additional analyses may be needed and/or may contradict such results, the risk of the ability of the FUROSCIX On-Body Infusor to appropriately deliver therapy, the receipt of regulatory approval for any of our product candidates or, if approved, the successful commercialization of such products, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies will not be repeated or observed in ongoing or future studies involving our product candidates, risks related to manufacturing and quality assurances processes, and the risk that the current COVID-19 pandemic will impact the Company’s device validation, drug stability testing, and other operations. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the sections entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 and the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 on file with the Securities and Exchange Commission, available at the Securities and Exchange Commission’s website at www.sec.gov, as well as discussions of potential risks, uncertainties and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All information in this current report is as of the date of the current report, and the Company undertakes no duty to update this information unless required by law.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

No.

   Description
  1.1    Underwriting Agreement, dated November 22, 2022, between scPharmaceuticals Inc., SVB Securities LLC and Cowen and Company, LLC, as representatives of the several underwriters named therein.
  4.1    Form of Pre-funded Warrant.
  5.1    Opinion of Latham & Watkins LLP.
23.1    Consent of Latham & Watkins LLP (included in Exhibit 5.1).
104    Cover Page Interactive Data File (embedded within the inline XBRL document).


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    SCPHARMACEUTICALS INC.
Date: November 23, 2022     By:  

/s/ John H. Tucker

    Name:   John H. Tucker
    Title:   President and Chief Executive Officer
EX-1.1 2 d240360dex11.htm EX-1.1 EX-1.1

Exhibit 1.1

6,620,000 Shares

Pre-Funded Warrants to Purchase 2,905,000 Shares of Common Stock

scPharmaceuticals Inc.

UNDERWRITING AGREEMENT

November 22, 2022

SVB SECURITIES LLC

COWEN AND COMPANY, LLC

As Representatives of the several Underwriters

c/o SVB SECURITIES LLC

53 State Street, 40th Floor

Boston, MA 02109

c/o COWEN AND COMPANY, LLC

599 Lexington Avenue

New York, NY 10022

Ladies and Gentlemen:

Introductory. scPharmaceuticals Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of (i) 6,620,000 shares of its common stock, par value $0.0001 per share (the “Shares”) and (ii) pre-funded warrants to purchase an aggregate of up to an additional 2,905,000 Shares at an exercise price equal to $0.001 per share (the “Pre-funded Warrants”). The 6,620,000 Shares to be sold by the Company are called the “Offered Shares”. The Offered Shares and Pre-funded Warrants are called the “Securities”. SVB Securities LLC (“SVB Securities”) and Cowen and Company, LLC (“Cowen”) agreed to act as representatives of the several Underwriters (in such capacity, the “Representatives”) in connection with the offering and sale of the Securities. To the extent there are no additional underwriters listed on Schedule A, the term “Representatives” as used in this underwriting agreement (the “Agreement”) shall mean you, as Underwriters, and the term “Underwriters” shall mean either the singular or the plural, as the context requires. As used herein, “Warrant Shares” means the Shares issuable upon exercise of the Pre-funded Warrants.

The Company has prepared and filed with the Securities and Exchange Commission (the “Commission”) a shelf registration statement on Form S-3, File No. 333-254637, including a base prospectus (the “Base Prospectus”) to be used in connection with the public offering and sale of the Securities. Such registration statement, as amended, including the financial statements, exhibits and schedules thereto, in the form in which it became effective under the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder (collectively, the “Securities Act”), including all documents incorporated or deemed to be incorporated by reference therein and any information deemed to be a part thereof at the time of effectiveness pursuant to Rule 430A or Rule 430B under the Securities Act, is called the “Registration Statement.” Any registration statement filed by the Company pursuant to Rule 462(b) under the Securities Act in connection with the offer and sale of the Securities is called the “Rule 462(b) Registration Statement,” and from and after the date and time of filing of any such Rule 462(b) Registration Statement the term “Registration Statement” shall include the Rule 462(b) Registration Statement. The preliminary prospectus supplement filed on November 21, 2022 describing the Securities and the offering thereof (the “Preliminary Prospectus Supplement”), together with the Base Prospectus, is called the “Preliminary Prospectus,” and the Preliminary Prospectus and any other prospectus


supplement to the Base Prospectus in preliminary form that describes the Securities and the offering thereof and is used prior to the filing of the Prospectus (as defined below), together with the Base Prospectus, is called a “preliminary prospectus.” As used herein, the term “Prospectus” shall mean the final prospectus supplement to the Base Prospectus that describes the Securities and the offering thereof (the “Final Prospectus Supplement”), together with the Base Prospectus, in the form first used by the Underwriters to confirm sales of the Securities or in the form first made available to the Underwriters by the Company to meet requests of purchasers pursuant to Rule 173 under the Securities Act. References herein to the Preliminary Prospectus, any preliminary prospectus and the Prospectus shall refer to both the prospectus supplement and the Base Prospectus components of such prospectus.

As used herein, “Applicable Time” is 8:00 a.m. (New York City time) on November 22, 2022. As used herein, “free writing prospectus” has the meaning set forth in Rule 405 under the Securities Act, and “Time of Sale Prospectus” means the Preliminary Prospectus, as amended or supplemented immediately prior to the Applicable Time, together with the free writing prospectuses, if any, identified in Schedule B-1 hereto and the pricing information identified in Schedule B-2 hereto. As used herein, Road Show means a “road show” (as defined in Rule 433 under the Securities Act) relating to the offering of the Securities contemplated hereby that is a “written communication” (as defined in Rule 405 under the Securities Act). As used herein, “Rule 163B Written Communication” means each written communication (within the meaning of Rule 405 under the Securities Act) that is made in reliance on Rule 163B under the Securities Act by the Company or any person authorized to act on behalf of the Company to one or more potential investors that are, or are reasonably believed to be, qualified institutional buyers (“QIBs”) and/or institutions that are, or reasonably believed to be, accredited investors (“IAIs”), as such terms are respectively defined in Rule 144A and Rule 501(a) under the Securities Act, to determine whether such investors might have an interest in the offering of the Securities; “Rule 163B Oral Communication” means each oral communication, if any, made in reliance on Rule 163B of the Securities Act by the Company or any person authorized to act on behalf of the Company made to one or more QIBs and/or one or more IAIs to determine whether such investors might have an interest in the offering of the Securities; “Marketing Materials” means any materials or information provided to investors by, or with the approval of, the Company in connection with the marketing of the offering of the Securities, including any roadshow or investor presentations made to investors by the Company (whether in person or electronically); and “Permitted Rule 163B Communication” means the Rule 163B Written Communication(s) and Marketing Materials listed on Schedule C attached hereto.

All references in this Agreement to the Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus and the Prospectus shall include the documents incorporated or deemed to be incorporated by reference therein. All references in this Agreement to financial statements and schedules and other information which are “contained,” “included” or “stated” in, or “part of” the Registration Statement, the Rule 462(b) Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, the Time of Sale Prospectus or the Prospectus, and all other references of like import, shall be deemed to mean and include all such financial statements and schedules and other information which is or is deemed to be incorporated by reference in the Registration Statement, the Rule 462(b) Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, the Time of Sale Prospectus or the Prospectus, as the case may be. All references in this Agreement to amendments or supplements to the Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, the Time of Sale Prospectus or the Prospectus shall be deemed to mean and include the filing of any document under the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (collectively, the “Exchange Act”) that is or is deemed to be incorporated by reference in the Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, or the Prospectus, as the case may be.

 

2


All references in this Agreement to (i) the Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, the Prospectus or any amendments or supplements to any of the foregoing, or any free writing prospectus, shall include any copy thereof filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval System (“EDGAR”) and (ii) the Prospectus shall be deemed to include any “electronic Prospectus” provided for use in connection with the offering of the Securities as contemplated by Section 3(n) of this Agreement.

In the event that the Company has only one subsidiary, then all references herein to “subsidiaries” of the Company shall be deemed to refer to such single subsidiary, mutatis mutandis.

The Company hereby confirms its agreements with the Underwriters as follows:

Section 1. Representations and Warranties of the Company.

The Company hereby represents, warrants and covenants to each Underwriter, as of the date of this Agreement, as of the Closing Date (as hereinafter defined), as follows:

(a) Compliance with Registration Requirements. The Registration Statement has become effective under the Securities Act. The Company has complied, to the Commission’s satisfaction, with all requests of the Commission for additional or supplemental information, if any. No stop order suspending the effectiveness of the Registration Statement is in effect and no proceedings for such purpose have been instituted or are pending or, to the knowledge of the Company, are contemplated or threatened by the Commission. At (i) the time the Registration Statement was originally filed with the Commission, and at the time the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “Annual Report”) was filed with the Commission, the Company met the then applicable requirements for the use of Form S-3 under the Securities Act and (ii) on the date of this Agreement, the Company meets the applicable requirements for the use of Form S-3 under the Securities Act, including, but not limited to, General Instruction I.B.1 of Form S-3. The documents incorporated or deemed to be incorporated by reference into the Registration Statement, the Time of Sale Prospectus and the Prospectus, at the time they were or hereafter are filed with the Commission, or became effective under the Exchange Act, as the case may be, complied and will comply in all material respects with the requirements of the Exchange Act.

(b) Disclosure. Each preliminary prospectus and the Prospectus when filed complied in all material respects with the Securities Act and, if filed by electronic transmission pursuant to EDGAR, was identical (except as may be permitted by Regulation S-T under the Securities Act) to the copy thereof delivered to the Underwriters for use in connection with the offer and sale of the Securities. Each of the Registration Statement and any post-effective amendment thereto, at the time it became or becomes effective, complied and will comply in all material respects with the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. As of the Applicable Time, the Time of Sale Prospectus did not, and at the Closing Date (as defined in Section 2), will not, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. The Prospectus, as of its date, did not, and at the Closing Date, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The representations and warranties set forth in the three immediately preceding sentences do not apply to statements in or omissions from the Registration Statement or any post-effective amendment thereto, or the Prospectus or the Time of Sale Prospectus, or any amendments or supplements thereto, made in reliance upon and in conformity with written information relating to any Underwriter furnished to the Company in writing by the Representatives expressly for use therein, it being understood and agreed that the only such information consists of the information described in Section 9(b) below. There are no contracts or other documents required to be described in the Time of Sale Prospectus or the Prospectus or to be filed as an exhibit to the Registration Statement which have not been described or filed as required.

 

3


(c) Free Writing Prospectuses; Road Show. As of the determination date referenced in Rule 164(h) under the Securities Act, the Company was not, is not or will not be (as applicable) an “ineligible issuer” in connection with the offering of the Securities pursuant to Rules 164, 405 and 433 under the Securities Act. Each free writing prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the requirements of the Securities Act. Each free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or that was prepared by or on behalf of or used or referred to by the Company complies or will comply in all material respects with the requirements of Rule 433 under the Securities Act, including timely filing with the Commission or retention and legending, as applicable, and each such free writing prospectus, as of its issue date and at all subsequent times through the completion of the public offer and sale of the Securities did not, does not and will not include any information that conflicted, conflicts or will conflict with the information contained in the Registration Statement, the Prospectus or any preliminary prospectus unless such information has been superseded or modified as of such time. Except for the free writing prospectuses, if any, identified in Schedule B, and electronic road shows, if any, furnished to you before first use, the Company has not prepared, used or referred to, and will not, without your prior written consent, prepare, use or refer to, any free writing prospectus. Each Road Show, when considered together with the Time of Sale Prospectus, did not, as of the Applicable Time, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.

(d) Distribution of Offering Material By the Company. Prior to the completion of the Underwriters’ distribution of the Securities, the Company has not distributed and will not distribute any offering material in connection with the offering and sale of the Securities other than the Registration Statement, the Time of Sale Prospectus, the Prospectus or any free writing prospectus reviewed and consented to by the Representatives, the free writing prospectuses, if any, identified on Schedule B hereto and any Permitted Rule 163B Communications.

(e) The Underwriting Agreement. This Agreement has been duly authorized, executed and delivered by the Company.

(f) Authorization of the Securities. The Offered Shares have been duly authorized for issuance and sale pursuant to this Agreement and, when issued and delivered by the Company against payment therefor pursuant to this Agreement, will be validly issued, fully paid and nonassessable, and the issuance and sale of the Offered Shares is not subject to any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase the Offered Shares. The Pre-funded Warrants have been duly authorized by the Company and, when executed and delivered by the Company pursuant to this Agreement, will be valid and binding agreements of the Company, enforceable against the Company in accordance with their terms, except as the enforcement thereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to or affecting the rights and remedies of creditors or by general equitable principles. The Warrant Shares have been duly authorized and validly reserved for issuance upon exercise of the Pre-funded Warrants in a number sufficient to meet the current exercise requirements. The Warrant Shares, when issued and delivered to and paid for by the Underwriters in accordance with the terms of this Agreement, will be duly and validly issued and fully paid and non-assessable and will conform to the descriptions thereof contained in the Time of Sale Prospectus and the Prospectus; and the issuance of the Warrant Shares is not subject to any preemptive or similar rights that have not been duly waived.

 

4


(g) No Applicable Registration or Other Similar Rights. There are no persons with registration or other similar rights to have any equity or debt securities registered for sale under the Registration Statement or included in the offering contemplated by this Agreement, except for such rights as have been duly waived.

(h) No Material Adverse Change. Except as otherwise disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus, subsequent to the respective dates as of which information is given in the Registration Statement, the Time of Sale Prospectus and the Prospectus: (i) there has been no material adverse change, or any development that would reasonably be expected to result in a material adverse change, in (A) the condition, financial or otherwise, or in the earnings, business, properties, operations, operating results, assets, liabilities or prospects, whether or not arising from transactions in the ordinary course of business, of the Company and its subsidiaries, considered as one entity or (B) the ability of the Company to consummate the transactions contemplated by this Agreement or perform its obligations hereunder (any such change being referred to herein as a “Material Adverse Change”); (ii) the Company and its subsidiaries, considered as one entity, have not incurred any material liability or obligation, indirect, direct or contingent, including without limitation any losses or interference with their business from fire, explosion, flood, earthquakes, accident or other calamity, whether or not covered by insurance, or from any strike, labor dispute or court or governmental action, order or decree, that are material, individually or in the aggregate, to the Company and its subsidiaries, considered as one entity, and have not entered into any material transactions not in the ordinary course of business; and (iii) there has not been any material decrease in the capital stock or any material increase in any short-term or long-term indebtedness of the Company or its subsidiaries and there has been no dividend or distribution of any kind declared, paid or made by the Company or, except for dividends paid to the Company or other subsidiaries, by any of the Company’s subsidiaries on any class of capital stock, or any repurchase or redemption by the Company or any of its subsidiaries of any class of capital stock.

(i) Independent Accountants. RSM US LLP, which has expressed its opinion with respect to the financial statements (which term as used in this Agreement includes the related notes thereto) filed with the Commission as a part of the Registration Statement, the Time of Sale Prospectus and the Prospectus, is (i) an independent registered public accounting firm as required by the Securities Act, the Exchange Act, and the rules of the Public Company Accounting Oversight Board (“PCAOB”), (ii) in compliance with the applicable requirements relating to the qualification of accountants under Rule 2-01 of Regulation S-X under the Securities Act and (iii) a registered public accounting firm as defined by the PCAOB whose registration has not been suspended or revoked and who has not requested such registration to be withdrawn.

(j) Financial Statements. The financial statements filed with the Commission as a part of the Registration Statement, the Time of Sale Prospectus and the Prospectus present fairly in all material respects the consolidated financial position of the Company and its subsidiaries as of the dates indicated and the results of their operations, changes in stockholders’ equity and cash flows for the periods specified. Such financial statements have been prepared in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) applied on a consistent basis throughout the periods involved, except as may be expressly stated in the related notes thereto and except in the case of unaudited financial statements, which are subject to normal and recurring year-end adjustments and do not contain certain footnotes as permitted by the applicable rules of the Commission. The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance with the Commission’s rules and guidelines applicable thereto. No other financial statements or supporting schedules are required to be included in the Registration Statement, the Time of Sale Prospectus or the Prospectus. The financial data incorporated by reference into each of the Registration Statement, the Time of Sale Prospectus and the Prospectus fairly present in all material respects the information set forth

 

5


therein on a basis consistent with that of the audited financial statements contained in the Registration Statement, the Time of Sale Prospectus and the Prospectus. To the Company’s knowledge, no person who has been suspended or barred from being associated with a registered public accounting firm, or who has failed to comply with any sanction pursuant to Rule 5300 promulgated by the PCAOB, has participated in or otherwise aided the preparation of, or audited, the financial statements, supporting schedules or other financial data filed with the Commission as a part of the Registration Statement, the Time of Sale Prospectus and the Prospectus.

(k) Companys Accounting System. The Company and each of its subsidiaries make and keep accurate books and records that are accurate in all material respects and maintain a system of internal accounting controls designed to provide reasonable assurance that: (i) transactions are executed in accordance with management’s general or specific authorization; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with U.S. GAAP and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v) the interactive data in eXtensible Business Reporting Language included or incorporated by reference into the Registration Statement, the Time of Sale Prospectus and the Prospectus fairly presents the information called for in all material respects and is prepared in accordance with the Commission’s rules and guidelines applicable thereto.

(l) Disclosure Controls and Procedures; Deficiencies in or Changes to Internal Control Over Financial Reporting. Except as otherwise described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, the Company has established and maintains disclosure controls and procedures (as defined in Rules 13a-15 and 15d-15 under the Exchange Act), which are designed to ensure that material information relating to the Company is made known to the Company’s principal executive officer and its principal financial officer by others within those entities, particularly during the periods in which the periodic reports required under the Exchange Act are being prepared (it being understood that neither subsection (k) nor this subsection (l) requires the Company to comply with Section 404 of the Sarbanes-Oxley Act of 2002 as of an earlier date than it would otherwise be required to so comply under applicable law). Except as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, since the end of the Company’s most recent audited fiscal year, there have been no significant deficiencies or material weakness in the Company’s internal control over financial reporting (whether or not remediated) and no change in the Company’s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting. The Company is not aware of any change in its internal control over financial reporting that has occurred during its most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

(m) Incorporation and Good Standing of the Company. The Company has been duly incorporated and is validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation and has the corporate power and authority to own, lease and operate its properties and to conduct its business as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus and to enter into and perform its obligations under this Agreement. The Company is duly qualified as a foreign corporation to transact business and is in good standing in the Commonwealth of Massachusetts and each other jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to be so qualified or be in good standing would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change.

 

6


(n) Subsidiaries. Each of the Company’s “subsidiaries” (for purposes of this Agreement, as defined in Rule 405 under the Securities Act) has been duly incorporated or organized, as the case may be, and is validly existing as a corporation, partnership or limited liability company, as applicable, in good standing under the laws of the jurisdiction of its incorporation or organization and has the power and authority (corporate or other) to own, lease and operate its properties and to conduct its business as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus. Each of the Company’s subsidiaries is duly qualified as a foreign corporation, partnership or limited liability company, as applicable, to transact business and is in good standing in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to be so qualified or be in good standing would not reasonably be expected to result in a Material Adverse Change. All of the issued and outstanding capital stock or other equity or ownership interests of each of the Company’s subsidiaries have been duly authorized and validly issued, are fully paid and nonassessable and are owned by the Company, directly or through subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance or adverse claim, except for any mortgage, pledge, lien, encumbrance or adverse claim disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus. None of the outstanding capital stock or equity interest in any subsidiary was issued in violation of preemptive or similar rights of any security holder of such subsidiary. The constitutive or organizational documents of each of the subsidiaries comply in all material respects with the requirements of applicable laws of its jurisdiction of incorporation or organization and are in full force and effect. As of the date of this Agreement, the Company does not own or control, directly or indirectly, any corporation, association or other entity other than scPharmaceuticals Securities Corporation and will not own or control, directly or indirectly, any corporation, association or other entity other than the subsidiaries listed in Exhibit 21 to the Company’s Annual Report on Form 10-K filed hereafter for its most recently completed fiscal year.

(o) Capitalization and Other Capital Stock Matters. The authorized, issued and outstanding capital stock of the Company is as set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus under the caption “Description of Capital Stock” (other than for subsequent issuances, if any, pursuant to employee benefit plans, or upon the exercise of outstanding options or warrants, in each case described in the Registration Statement, the Time of Sale Prospectus and the Prospectus). The Shares (including the Offered Shares and Pre-funded Warrants) conform (or will conform when issued pursuant to the terms of this Agreement, as applicable) in all material respects to the description thereof contained in the Time of Sale Prospectus. All of the issued and outstanding Shares have been duly authorized and validly issued, are fully paid and nonassessable and have been issued in compliance with all applicable federal and state securities laws. None of the outstanding Shares was issued in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company. There are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any capital stock of the Company other than those described in the Registration Statement, the Time of Sale Prospectus and the Prospectus. The descriptions of the Company’s stock option, stock bonus and other stock plans or arrangements, and the options or other rights granted thereunder, set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus accurately and fairly presents in all material respects the information required to be shown with respect to such plans, arrangements, options and rights.

(p) Stock Exchange Listing. The Shares are registered pursuant to Section 12(b) or 12(g) of the Exchange Act and are listed on the Nasdaq Global Select Market (“Nasdaq”), and the Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Shares under the Exchange Act or delisting the Shares from Nasdaq, nor has the Company received any notification that the Commission or Nasdaq is contemplating terminating such registration or listing. To the Company’s knowledge, it is in compliance with all applicable listing requirements of Nasdaq.

 

7


(q) Non-Contravention of Existing Instruments; No Further Authorizations or Approvals Required. Neither the Company nor any of its subsidiaries is in violation of its charter or by-laws, partnership agreement or operating agreement or similar organizational documents, as applicable, or is in default (or, with the giving of notice or lapse of time, would be in default) (“Default”) under any indenture, loan, credit agreement, note, lease, license agreement, contract, franchise or other instrument (including, without limitation, any pledge agreement, security agreement, mortgage or other instrument or agreement evidencing, guaranteeing, securing or relating to indebtedness) to which the Company or any of its subsidiaries is a party or by which it or any of them may be bound, or to which any of their respective properties or assets are subject (each, an “Existing Instrument”), except for such Defaults as could not be expected, individually or in the aggregate, to result in a Material Adverse Change. The Company’s execution, delivery and performance of this Agreement, consummation of the transactions contemplated hereby and by the Registration Statement, the Time of Sale Prospectus and the Prospectus and the issuance and sale of the Securities, and upon exercise of the Pre-funded Warrants, the issuance of the Warrant Shares(including the use of proceeds from the sale of the Securities as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus under the caption “Use of Proceeds”) (i) have been duly authorized by all necessary corporate action and will not result in any violation of the provisions of the charter or by-laws, partnership agreement or operating agreement or similar organizational documents, as applicable, of the Company or any subsidiary, (ii) will not conflict with or constitute a breach of, or Default or a Debt Repayment Triggering Event (as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company or any of its subsidiaries pursuant to, or require the consent of any other party to, any Existing Instrument and (iii) will not result in any violation of any law, administrative regulation or administrative or court decree applicable to the Company or any of its subsidiaries, except for such conflicts, breaches, Defaults, liens, charges, encumbrances or violations specified in subsections (ii) and (iii) above that would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change. No consent, approval, authorization or other order of, or registration or filing with, any court or other governmental or regulatory authority or agency, is required for the Company’s execution, delivery and performance of this Agreement and consummation of the transactions contemplated hereby and by the Registration Statement, the Time of Sale Prospectus and the Prospectus, except such as have been obtained or made by the Company and are in full force and effect under the Securities Act and such as may be required under applicable state securities or blue sky laws or the Financial Industry Regulatory Authority (“FINRA”). As used herein, a “Debt Repayment Triggering Event” means any event or condition which gives, or with the giving of notice or lapse of time would give, the holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder’s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company or any of its subsidiaries.

(r) Compliance with Laws. The Company has been and is in compliance with all applicable laws, rules and regulations, except where failure to be so in compliance could not be expected, individually or in the aggregate, to result in a Material Adverse Change.

(s) No Material Actions or Proceedings. Except as otherwise disclosed in the Time of Sale Prospectus or the Prospectus, there is no action, suit, proceeding, inquiry or investigation brought by or before any legal or governmental entity now pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of its subsidiaries, which could be expected, individually or in the aggregate, to result in a Material Adverse Change. No material labor dispute with the employees of the Company or any of its subsidiaries, or with the employees of any principal supplier, manufacturer, customer or contractor of the Company, exists or, to the knowledge of the Company, is threatened or imminent.

 

8


(t) Intellectual Property Rights. Except as otherwise disclosed in the Registration Statement, the Time of Sale Prospectus or the Prospectus, the Company and its subsidiaries owns, or have obtained valid and enforceable licenses for, the inventions, patent applications, patents, trademarks, trade names, service names, copyrights, trade secrets and other intellectual property described in the Registration Statement, the Time of Sale Prospectus and the Prospectus as being owned or licensed by them or which are necessary for the conduct of their respective businesses as currently conducted or, to the Company’s knowledge, as currently proposed to be conducted (with respect to the commercialization of products and product candidates described in the Registration Statement, the Time of Sale Prospectus and the Prospectus), except where the failure to own or license such rights would not, individually or in the aggregate, result in a Material Adverse Change (collectively, “Intellectual Property”). To the Company’s knowledge: (i) there are no third parties who have rights to any Intellectual Property, except for customary reversionary rights of third-party licensors with respect to Intellectual Property that is disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus as licensed to the Company or one or more of its subsidiaries; and (ii) there is no infringement by third parties of any Intellectual Property. There is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others: (A) challenging the Company’s or its subsidiaries’ rights in or to any Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; (B) challenging the validity, enforceability or scope of any Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; or (C) asserting that the Company or any of its subsidiaries infringes or otherwise violates, or would, upon the commercialization of any product or service described in the Registration Statement, the Time of Sale Prospectus or the Prospectus as under development, infringe or violate, any patent, trademark, trade name, service name, copyright, trade secret or other proprietary rights of others, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim. The Company and its subsidiaries have complied with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or any subsidiary, and all such agreements are in full force and effect. The products and product candidates described in the Registration Statement, the Time of Sale Prospectus and the Prospectus as under development by the Company or one or more of its subsidiaries fall within the scope of the claims of one or more patents or pending patent applications owned by, or licensed to, the Company. No employee of the Company or any of its subsidiaries is in or has ever been in violation in any material respect of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, non-disclosure agreement or any restrictive covenant to or with a former employer where the basis of such violation relates to such employee’s employment with the Company or any of its subsidiaries, or actions undertaken by the employee while employed with the Company or any of its subsidiaries.

(u) All Necessary Permits, etc. Except as otherwise disclosed in the Time of Sale Prospectus or the Prospectus, the Company and each subsidiary possess, or qualify for, applicable exemptions to, such valid and current certificates, authorizations or permits required by state, federal or foreign regulatory agencies or bodies to conduct their respective businesses as currently conducted and as described in the Registration Statement, the Time of Sale Prospectus or the Prospectus (“Permits”), except where the failure to possess the same or so qualify would not reasonably be expected, individually, or in the aggregate, to result in a Material Adverse Change. Neither the Company nor any of its subsidiaries is in violation of, or is in default under, any of the Permits or has received any notice of proceedings relating to the revocation or modification of, or non-compliance with, any of the Permits, except for any such violations, defaults, or proceedings relating to the revocation or modification of, or non-compliance with, any such Permits that would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change.

 

9


(v) Title to Properties. Except as otherwise disclosed in the Time of Sale Prospectus and the Prospectus, the Company and its subsidiaries have good and marketable title to all of the real and personal property and other assets reflected as owned in the financial statements referred to in Section 1(j) above (or elsewhere in the Registration Statement, the Time of Sale Prospectus or the Prospectus), in each case free and clear of any security interests, mortgages, liens, encumbrances, equities, adverse claims and other defects, except such as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change. The real property, improvements, equipment and personal property held under lease by the Company or its subsidiary are held under valid and enforceable leases, with such exceptions as are not material and do not materially interfere with the use made or proposed to be made of such real property, improvements, equipment or personal property by the Company or such subsidiary.

(w) Tax Law Compliance. The Company and its subsidiaries have filed all necessary federal, state and foreign income and franchise tax returns or have properly requested extensions thereof and have paid all material taxes required to be paid by any of them and, if due and payable, any related or similar assessment, fine or penalty levied against any of them except as may be being contested in good faith and by appropriate proceedings. The Company has made adequate charges, accruals and reserves in the applicable financial statements referred to in Section 1(j) above in respect of all material federal, state and foreign income and franchise taxes for all periods as to which the tax liability of the Company or any of its subsidiaries has not been finally determined.

(x) Insurance. Except as otherwise disclosed in the Prospectus, each of the Company and its subsidiaries is insured by recognized and reputable institutions with policies in such amounts and with such deductibles and covering such risks as are generally deemed adequate and customary for their businesses including, but not limited to, policies covering real and personal property owned or leased by the Company and its subsidiaries against theft, damage, destruction, acts of vandalism and earthquakes and policies covering the Company and its subsidiaries for product liability claims and clinical trial liability claims. The Company has no reason to believe that it or any of its subsidiaries will not be able (i) to renew its existing insurance coverage as and when such policies expire or (ii) to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change. Neither the Company nor any of its subsidiaries has been denied any insurance coverage which it has sought or for which it has applied.

(y) Compliance with Environmental Laws. Except as described in the Time of Sale Prospectus and the Prospectus and except as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change: (i) the Company is not in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products (collectively, “Hazardous Materials”) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, “Environmental Laws”); (ii) the Company and its subsidiaries have all permits, authorizations and approvals required under any applicable Environmental Laws and are each in compliance with its requirements; (iii) there are no pending or, to the knowledge of the Company, threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company or any of its subsidiaries; and (iv) there are no events or circumstances that might reasonably be expected to form the basis of an order for clean-up or remediation, or an action, suit or proceeding by any private party or governmental body or agency, against or affecting the Company or any of its subsidiaries relating to Hazardous Materials or any Environmental Laws.

 

10


(z) ERISA Compliance. Except as otherwise disclosed in the Time of Sale Prospectus or the Prospectus, the Company and its subsidiaries and any “employee benefit plan” (as defined under the Employee Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, “ERISA”)) established or maintained by the Company or its subsidiaries or their “ERISA Affiliates” (as defined below) are in compliance in all material respects with ERISA. “ERISA Affiliate” means, with respect to the Company or any of its subsidiaries, any member of any group of organizations described in Sections 414(b), (c), (m) or (o) of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder (the “Code”) of which the Company or such subsidiary is a member. Except as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change, (i) no “reportable event” (as defined under ERISA), for which notice has not been waived, has occurred or is reasonably expected to occur with respect to any “employee benefit plan” established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates; (ii) no “employee benefit plan” established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates, if such “employee benefit plan” were terminated, would have any “amount of unfunded benefit liabilities” (as defined under ERISA); and (iii) neither the Company, its subsidiaries nor any of their ERISA Affiliates has incurred or reasonably expects to incur any liability under (x) Title IV of ERISA with respect to termination of, or withdrawal from, any “employee benefit plan” or (y) Sections 412, 4971, 4975 or 4980B of the Code. Each employee benefit plan established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates that is intended to be qualified under Section 401(a) of the Code has received a favorable determination or opinion letter from the Internal Revenue Service or has time remaining to do so, and to the knowledge of the Company nothing has occurred, whether by action or failure to act, which would cause the loss of such qualification.

(aa) Company Not an Investment Company. The Company and its subsidiaries are not, and will not be, either after receipt of payment for the Securities or after the application of the proceeds therefrom as described under “Use of Proceeds” in the Registration Statement, the Time of Sale Prospectus or the Prospectus, required to register as an “investment company” under the Investment Company Act of 1940, as amended (the Investment Company Act).

(bb) No Price Stabilization or Manipulation; Compliance with Regulation M. The Company and its subsidiaries have not taken, directly or indirectly, without giving effect to activities by the Underwriters, any action designed to or that might reasonably be expected to cause or result in stabilization or manipulation of the price of the Shares or of any “reference security” (as defined in Rule 100 of Regulation M under the Exchange Act (Regulation M)) with respect to the Shares, whether to facilitate the sale or resale of the Offered Shares, the Warrant Shares or otherwise, and have taken no action which would directly or indirectly violate Regulation M.

(cc) Related-Party Transactions. There are no business relationships or related-party transactions involving the Company, its subsidiaries or any other person required to be described in the Registration Statement, the Time of Sale Prospectus or the Prospectus that have not been described as required.

(dd) FINRA Matters. All of the information provided to the Underwriters or to counsel for the Underwriters by the Company, its officers and directors and, to the knowledge of the Company, its counsel and the holders of any securities (debt or equity) or options to acquire any securities of the Company in connection with the offering of the Securities is true, complete, correct and compliant with FINRA’s rules and any letters, filings or other supplemental information provided to FINRA pursuant to FINRA Rules or Nasdaq Conduct Rules is true, complete and correct.

(ee) Parties to Lock-Up Agreements. The Company has furnished to the Underwriters a letter agreement in the form attached hereto as Exhibit A (the “Lock-up Agreement”) from each of the directors, officers and other persons listed on Exhibit B, as well as certain other beneficial owners of the Company’s capital stock, as agreed upon by the Underwriters.

 

11


(ff) Statistical and Market-Related Data. All statistical, demographic and market-related data included in the Registration Statement, the Time of Sale Prospectus or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate. To the extent required, the Company has obtained the written consent to the use of such data from such sources.

(gg) Sarbanes-Oxley Act. There is, and has been, no failure on the part of the Company, its subsidiaries or any of their directors or officers, in their capacities as such, to comply with any applicable provision of the Sarbanes-Oxley Act of 2002, as amended and the rules and regulations promulgated in connection therewith, including Section 402 related to loans and Sections 302 and 906 related to certifications.

(hh) No Unlawful Contributions or Other Payments. Neither the Company, the Company’s subsidiaries nor, to the knowledge of the Company, any employee or agent of the Company or its subsidiaries, has made any contribution or other payment to any official of, or candidate for, any federal, state or foreign office in violation of any applicable law or of the character required to be disclosed in the Registration Statement, the Time of Sale Prospectus or the Prospectus.

(ii) Anti-Corruption and Anti-Bribery Laws. Neither the Company nor any of its subsidiaries nor any director, officer, or employee of the Company or any of its subsidiaries, nor to the knowledge of the Company, any agent, affiliate or other person acting on behalf of the Company or any of its subsidiaries has, in the course of its actions for, or on behalf of, the Company or any of its subsidiaries (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (ii) made or taken any act in furtherance of an offer, promise, or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee, including of any government-owned or controlled entity or public international organization, or any political party, party official, or candidate for political office; (iii) violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”), UK Bribery Act 2010, or any other applicable anti-bribery or anti-corruption law; or (iv) made, offered, authorized, requested, or taken an act in furtherance of any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment or benefit. The Company and its subsidiaries and, to the knowledge of the Company, the Company’s affiliates have conducted their respective businesses in compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith.

(jj) Money Laundering Laws. The operations of the Company and its subsidiaries are, and have been conducted at all times, in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or similar applicable rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the “Money Laundering Laws”) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

(kk) Sanctions. Neither the Company nor any of its subsidiaries, directors, officers, or employees, nor, to the knowledge of the Company, after due inquiry, any agent, affiliate or other person acting on behalf of the Company or any of its subsidiaries is currently the subject or the target of any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury or

 

12


the U.S. Department of State, the United Nations Security Council, the European Union, Her Majesty’s Treasury of the United Kingdom, or other relevant sanctions authority (collectively, “Sanctions”); nor is the Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject or the target of Sanctions, including, without limitation, Cuba, Iran, North Korea, Sudan, Syria, Russia, and the Donetsk, Luhansk and Crimea regions of Ukraine (each, a “Sanctioned Country”); and the Company will not directly or indirectly use the proceeds of this offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, or any joint venture partner or other person or entity, for the purpose of financing the activities of or business with any person, or in any country or territory, that at the time of such financing, is the subject or the target of Sanctions or in any other manner that will result in a violation by any person (including any person participating in the transaction whether as underwriter, advisor, investor or otherwise) of applicable Sanctions. For the past five years, the Company and its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country.

(ll) Brokers. Except pursuant to this Agreement, there is no broker, finder or other party that is entitled to receive from the Company or its subsidiaries any brokerage or finder’s fee or other fee or commission as a result of any transactions contemplated by this Agreement.

(mm) Forward-Looking Statements. Each financial or operational projection or other “forward-looking statement” (as defined by Section 27A of the Securities Act or Section 21E of the Exchange Act) contained in the Registration Statement, the Time of Sale Prospectus or the Prospectus (i) was so included by the Company in good faith and with reasonable basis after due consideration by the Company of the underlying assumptions, estimates and other applicable facts and circumstances and (ii) is accompanied by meaningful cautionary statements identifying those factors that could cause actual results to differ materially from those in such forward-looking statement. No such statement was made with the knowledge of an executive officer or director of the Company that is was false or misleading.

(nn) Emerging Growth Company Status. From the time of initial filing of the Registration Statement to the Commission through the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the Securities Act (an “Emerging Growth Company”).

(oo) Clinical Data and Regulatory Compliance. The preclinical tests and clinical trials, and other studies (collectively, “studies”) that are described in, or the results of which are referred to in, the Registration Statement, the Time of Sale Prospectus or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures and all applicable laws and regulations, including, without limitation, 21 C.F.R. Parts 50, 54, 56, 58, 312 and 812; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement, the Time of Sale Prospectus or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the “Regulatory Agencies”); neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement, the Time of Sale Prospectus or the Prospectus; and the Company and its subsidiaries have each operated and currently is in compliance in all material respects with all applicable rules, regulations and policies of the Regulatory Agencies.

 

13


(pp) Healthcare Regulatory Compliance. The Company and its subsidiaries have operated and are currently in compliance in all material respects with all applicable Health Care Laws (defined herein), and have not engaged in activities which are, as applicable, cause for false claims liability, civil penalties, or mandatory or permissive exclusion from Medicare, Medicaid, or any other state or federal health care program. For purposes of this Agreement, “Health Care Laws” shall mean the Federal Food, Drug, and Cosmetic Act (21 U.S.C. §§ 301 et seq.); the federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); the civil False Claims Act (31 U.S.C. §§ 3729 et seq.); the criminal False Claims Act (42 U.S.C. § 1320a-7b(a)); all criminal laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. Sections 286, 287, 1035, 1347 and 1349, and the health care fraud criminal provisions under the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. § 1320d et seq.) (“HIPAA”); the exclusion laws (42 U.S.C. § 1320a-7); the civil monetary penalties law (42 U.S.C. § 1320a-7a); the Physician Payment Sunshine Act (42 U.S.C. § 1320a-7h); HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. §§ 17921 et seq.); the Medicare statute (Title XVIII of the Social Security Act); the Medicaid statute (Title XIX of the Social Security Act); the regulations promulgated pursuant to such laws and any other similar local, state or federal law and regulations. Neither the Company nor any of its subsidiaries has received any U.S. Food and Drug Administration (“FDA”) Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence, communication or notice from the U.S. Food and Drug Administration or any other governmental or regulatory authority alleging or asserting noncompliance with any Health Care Laws, and, to the Company’s knowledge, no claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action is threatened. Neither the Company nor any of its subsidiaries is a party to or has any ongoing reporting obligations pursuant to any corporate integrity agreements, deferred prosecution agreements, monitoring agreements, consent decrees, settlement orders, plans of correction or similar agreements with or imposed by any governmental or regulatory authority. Neither the Company, any of its subsidiaries nor any of their respective employees, officers, directors or agents has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research, or, to the Company’s knowledge, is subject to a governmental inquiry, investigation, proceeding, or other similar action that would reasonably be expected to result in debarment, suspension or exclusion.

(qq) Healthcare Product Manufacturing. The manufacture of the Company’s and its subsidiaries’ products and product candidates by or on behalf of the Company and its subsidiaries is being conducted in compliance in all material respects with all applicable Health Care Laws, including, without limitation, the FDA’s current good manufacturing practice regulations at 21 CFR Part 820, and, to the extent applicable, the respective counterparts thereof promulgated by governmental authorities in countries outside the United States. Neither the Company nor any of its subsidiaries has had any manufacturing site (whether Company-owned, subsidiary-owned or that of a third party manufacturer for the Company’s or its subsidiaries’ product candidates) subject to a governmental authority (including FDA or the European Medicines Agency “EMA”) shutdown or import or export prohibition, nor received any FDA, EMA or other governmental authority “warning letters,” or “untitled letters” alleging or asserting material noncompliance with any applicable Health Care Laws, requests to make material changes to the Company’s or its subsidiaries’ product candidates, processes or operations, or similar correspondence or notice from the FDA, EMA or other governmental authority alleging or asserting material noncompliance with any applicable Health Care Laws, other than those that have been satisfactorily addressed and/or closed with the FDA, EMA or other governmental authority. To the knowledge of the Company, neither the FDA, EMA or any other governmental authority is considering such action.

(rr) Cybersecurity. The Company and its subsidiaries’ information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications and databases (collectively, “IT Systems”) are adequate for, and operate and perform in all material respects as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and

 

14


other corruptants. The Company and its subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative controls, policies and procedures, and safeguards to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data, including “Personal Data,” used in connection with their business. “Personal Data” means (i) a natural person’s name, street address, telephone number, e-mail address, photograph, social security number or tax identification number, driver’s license number, passport number, credit card number, bank information or customer or account number; (ii) any information which would qualify as “personally identifying information” under the Federal Trade Commission Act, as amended, (iii) “personal data” as defined by the European Union General Data Protection Regulation (EU 2016/670) (“GDPR”); (iv) any information which would qualify as “protected health information” under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act; and (v) any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified person’s health or sexual orientation. There have been no breaches, violations, outages or unauthorized uses of or access to same, except for those that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents under internal review or investigations relating to the same. The Company and its subsidiaries are presently in material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification.

(ss) Compliance with Data Privacy Laws. The Company and its subsidiaries are, and at all prior times were, in material compliance with all applicable state and federal data privacy and security laws and regulations, including without limitation HIPAA, and the Company and its subsidiaries have taken commercially reasonable actions to prepare to comply with, and since May 25, 2018, have been and currently are in compliance with, the GDPR (collectively, the “Privacy Laws”). To ensure compliance with the Privacy Laws, the Company and its subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material respects with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling and analysis of Personal Data (the “Policies”). The Company and its subsidiaries have at all times made all disclosures to users or customers required by applicable laws and regulatory rules or requirements, and none of such disclosures made or contained in any Policy have, to the knowledge of the Company, been inaccurate or in violation of any applicable laws and regulatory rules or requirements in any material respect. The Company further certifies that neither it nor any subsidiary: (i) has received notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or condition that could reasonably be expected to result in any such notice; (ii) is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law; or (iii) is a party to any order, decree or agreement that imposes any obligation or liability under any Privacy Law.

(tt) No Rated Securities. There are no debt securities or preferred stock of, or guaranteed by, the Company that are rated by a “nationally recognized statistical rating organization” as that term is used in Rule 15c3-1(c)(2)(vi)(F) under the Exchange Act. Any certificate signed by any officer of the Company or any of its subsidiaries and delivered to any Underwriter or to counsel for the Underwriters in connection with the offering, or the purchase and sale, of the Securities shall be deemed a representation and warranty by the Company (and not by such officer in his or her personal capacity) to each Underwriter as to the matters covered thereby.

 

15


The Company has a reasonable basis for making each of the representations set forth in this Section 1. The Company acknowledges that the Underwriters and, for purposes of the opinions to be delivered pursuant to Section 6 hereof, counsel to the Company and counsel to the Underwriters, will rely upon the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance.

Section 2. Purchase, Sale and Delivery of the Securities.

(a) The Securities. Upon the terms herein set forth, the Company agrees to issue and sell to the several Underwriters an aggregate of 6,620,000 Offered Shares and 2,905,000 Pre-funded Warrants. On the basis of the representations, warranties and agreements herein contained, and upon the terms but subject to the conditions herein set forth, the Underwriters agree, severally and not jointly, to purchase from the Company the respective number of Offered Shares and Pre-funded Warrants set forth opposite their names on Schedule A. The purchase price per Offered Share to be paid by the several Underwriters to the Company shall be $4.935 per share. The purchase price per Pre-funded Warrant to be paid by the purchasers thereof shall be $4.93406 per Pre-funded Warrant

(b) The Closing Date. Delivery of certificates for the Securities to be purchased by the Underwriters and payment therefor shall be made at the offices of Goodwin Procter LLP (or such other place as may be agreed to by the Company and the Representatives) at 9:00 a.m. New York City time, on November 25, 2022, or such other time not later than 1:30 p.m. New York City time, on November 25, 2022 as the Representatives shall designate by notice to the Company (the time and date of such closing are called the “Closing Date”). The Company hereby acknowledges that circumstances under which the Representatives may provide notice to postpone the Closing Date as originally scheduled include, but are not limited to, any determination by the Company or the Representatives to recirculate to the public copies of an amended or supplemented Prospectus or a delay as contemplated by the provisions of Section 11.

(c) Public Offering of the Securities. The Representatives hereby advise the Company that the Underwriters intend to offer for sale to the public, initially on the terms set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus, their respective portions of the Offered Shares as soon after this Agreement has been executed as the Representatives, in their sole judgment, have determined is advisable and practicable.

(d) Payment for the Securities. (i) Payment for the Securities shall be made at the Closing Date by wire transfer of immediately available funds to the order of the Company.

(ii) Notwithstanding anything to the contrary in this Section 2, the Company and the Representatives shall instruct purchasers of the Pre-funded Warrants to make payment for the Pre-funded Warrants at the Closing Date to the Company by wire transfer in immediately available funds to the account specified by the Company in lieu of payment by the Representatives for such Pre-funded Warrants, and the Company shall deliver such Pre-funded Warrants to such purchasers at the Closing Date in definitive form against such payment, in lieu of the Company’s obligation to deliver such Pre-funded Warrants to the Representatives; provided that the Representatives shall withhold $0.31494 per Pre-funded Warrant with respect to such Pre-funded Warrants as an offset against the payment owed by the Representatives to the Company with respect to the Firm Securities hereunder.

(iii) In the event that any purchaser of the Pre-funded Warrants in the public offering fails to make payment to the Company for all or part of the Pre-funded Warrants at the Closing Date, the Representatives agree to make a payment to the Company for such Pre-funded Warrants at a price per Pre-funded Warrant equal to $4.93406; provided, however, that the Representatives may elect, by written notice to the Company, to receive Offered Shares at the purchase price for the Firm Shares in lieu of all or a portion of such Pre-funded Warrants to be delivered to the Representatives under this Agreement.

 

16


(iv) It is understood that the Representatives have been authorized, for their own respective accounts and the accounts of the several Underwriters, to accept delivery of and receipt for, and make payment of the purchase price for, the Securities the Underwriters have agreed to purchase. Each of SVB Securities and Cowen individually and not as the Representatives of the Underwriters, may (but shall not be obligated to) make payment for any Securities to be purchased by any Underwriter whose funds shall not have been received by the Representatives by the Closing Date for the account of such Underwriter, but any such payment shall not relieve such Underwriter from any of its obligations under this Agreement.

(e) Delivery of the Securities. The Company shall deliver, or cause to be delivered, through the book entry facilities of the Depository Trust Company (“DTC”) for the accounts of the several Underwriters the Offered Shares to be sold by them at the Closing Date, against release of a wire transfer of immediately available funds for the amount of the purchase price therefor. The Company shall deliver the Pre-funded Warrants to the purchasers thereof at the Closing Date in definitive form against such payment. The Securities shall be delivered to such accounts and in such denominations as the Representatives shall have requested at least two full business days prior to the Closing Date and shall be made available for inspection on the business day preceding the Closing Date at a location in New York City as the Representatives may designate. Time shall be of the essence, and delivery at the time and place specified in this Agreement is a further condition to the obligations of the Underwriters.

Section 3. Additional Covenants.

The Company further covenants and agrees with each Underwriter as follows:

(a) Delivery of Registration Statement, Time of Sale Prospectus and Prospectus. The Company shall furnish to you in New York City, without charge, prior to 10:00 a.m. New York City time on the business day next succeeding the date of this Agreement and during the period when a prospectus relating to the Securities is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) in connection with sales of the Securities, as many copies of the Time of Sale Prospectus, the Prospectus and any supplements and amendments thereto or to the Registration Statement as you may reasonably request.

(b) Representatives Review of Proposed Amendments and Supplements. During the period when a prospectus relating to the Securities is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule), the Company (i) will furnish to the Representatives for review, a reasonable period of time prior to the proposed time of filing of any proposed amendment or supplement to the Registration Statement, a copy of each such amendment or supplement and (ii) will not amend or supplement the Registration Statement (including any amendment or supplement through incorporation of any report filed under the Exchange Act) without the Representatives’ prior written consent, which consent shall not be unreasonably withheld. Prior to amending or supplementing any preliminary prospectus, the Time of Sale Prospectus or the Prospectus (including any amendment or supplement through incorporation of any report filed under the Exchange Act) the Company shall furnish to the Representatives for review, a reasonable amount of time prior to the time of filing or use of the proposed amendment or supplement, a copy of each such proposed amendment or supplement. The Company shall not file or use any such proposed amendment or supplement without the Representatives’ prior written consent, which consent shall not be unreasonably withheld. The Company shall file with the Commission within the applicable period specified in Rule 424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule.

 

17


(c) Free Writing Prospectuses. The Company shall furnish to the Representatives for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of each proposed free writing prospectus or any amendment or supplement thereto prepared by or on behalf of, used by, or referred to by the Company, and the Company shall not file, use or refer to any proposed free writing prospectus or any amendment or supplement thereto without the Representatives’ prior written consent, which consent shall not be unreasonably withheld. The Company shall furnish to each Underwriter, without charge, as many copies of any free writing prospectus prepared by or on behalf of, used by or referred to by the Company as such Underwriter may reasonably request. If at any time when a prospectus is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) in connection with sales of the Securities (but in any event if at any time through and including the Closing Date) there occurred or occurs an event or development as a result of which any free writing prospectus prepared by or on behalf of, used by, or referred to by the Company conflicted or would conflict with the information contained in the Registration Statement or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at such time, not misleading, the Company shall promptly amend or supplement such free writing prospectus to eliminate or correct such conflict so that the statements in such free writing prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at such time, not misleading, as the case may be; provided, however, that prior to amending or supplementing any such free writing prospectus, the Company shall furnish to the Representatives for review, a reasonable amount of time prior to the proposed time of filing or use thereof, a copy of such proposed amended or supplemented free writing prospectus, and the Company shall not file, use or refer to any such amended or supplemented free writing prospectus without the Representatives’ prior written consent, which consent shall not be unreasonably withheld.

(d) Filing of Underwriter Free Writing Prospectuses. The Company shall not take any action that would result in an Underwriter or the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of such Underwriter that such Underwriter otherwise would not have been required to file thereunder.

(e) Amendments and Supplements to Time of Sale Prospectus. If the Time of Sale Prospectus is being used to solicit offers to buy the Securities at a time when the Prospectus is not yet available to prospective purchasers, and any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Time of Sale Prospectus so that the Time of Sale Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when delivered to a prospective purchaser, not misleading, or if any event shall occur or condition exist as a result of which the Time of Sale Prospectus conflicts with the information contained in the Registration Statement, or if, in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable law, the Company shall (subject to Section 3(b) and Section 3(c) hereof) promptly prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, either amendments or supplements to the Time of Sale Prospectus so that the statements in the Time of Sale Prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when delivered to a prospective purchaser, not misleading or so that the Time of Sale Prospectus, as amended or supplemented, will no longer conflict with the information contained in the Registration Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will comply with applicable law.

 

18


(f) Certain Notifications and Required Actions. After the date of this Agreement, the Company shall promptly advise the Representatives in writing of: (i) the receipt of any comments of, or requests for additional or supplemental information from, the Commission; (ii) the time and date of any filing of any post-effective amendment to the Registration Statement or any amendment or supplement to any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus or the Prospectus; (iii) the time and date that any post-effective amendment to the Registration Statement becomes effective; and (iv) the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto or any amendment or supplement to any preliminary prospectus, the Time of Sale Prospectus or the Prospectus or of any order preventing or suspending the use of any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus or the Prospectus, or of any proceedings to remove, suspend or terminate from listing or quotation the Shares from any securities exchange upon which they are listed for trading or included or designated for quotation, or of the threatening or initiation of any proceedings for any of such purposes. If the Commission shall enter any such stop order at any time, the Company will use its best efforts to obtain the lifting of such order at the earliest possible moment. Additionally, the Company agrees that it shall comply with all applicable provisions of Rule 424(b), Rule 433 and Rule 430B under the Securities Act and will use its reasonable efforts to confirm that any filings made by the Company under Rule 424(b) or Rule 433 were received in a timely manner by the Commission.

(g) Amendments and Supplements to the Prospectus and Other Securities Act Matters. During the Prospectus Delivery Period, if any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) to a purchaser, not misleading, or if in the opinion of the Representatives or counsel for the Underwriters it is otherwise necessary to amend or supplement the Prospectus to comply with applicable law, the Company agrees (subject to Section 3(b) and Section 3(c)) hereof to promptly prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) to a purchaser, not misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law. Neither the Representatives’ consent to, nor delivery of, any such amendment or supplement shall constitute a waiver of any of the Company’s obligations under Section 3(b) or Section 3(c). As used herein, the term “Prospectus Delivery Period” means such period of time after the first date of the public offering of the Shares as in the opinion of counsel for the Underwriters a prospectus relating to the Shares is required by law to be delivered (or required to be delivered but for Rule 172 under the Securities Act) in connection with sales of the Shares by any Underwriter or dealer.

(h) Blue Sky Compliance. The Company shall cooperate with the Representatives and counsel for the Underwriters to qualify or register the Securities for sale under (or obtain exemptions from the application of) the state securities or blue sky laws (or other foreign laws) of those jurisdictions reasonably designated by the Representatives, shall comply with such laws and shall continue such qualifications, registrations and exemptions in effect so long as required for the distribution of the Securities. The Company shall not be required to qualify as a foreign corporation or to take any action that would subject it to general service of process in any such jurisdiction where it is not presently qualified or where it would be subject to taxation as a foreign corporation. The Company will advise the Representatives promptly of the suspension of the qualification or registration of (or any such exemption relating to) the Securities for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such purpose, and in the event of the issuance of any order suspending such qualification, registration or exemption, the Company shall use its reasonable best efforts to obtain the withdrawal thereof at the earliest possible moment.

 

19


(i) Use of Proceeds. The Company shall apply the net proceeds from the sale of the Securities sold by it in the manner described under the caption “Use of Proceeds” in the Registration Statement, the Time of Sale Prospectus and the Prospectus.

(j) Transfer Agent. The Company shall continue to maintain, at its expense, a registrar and transfer agent for the Shares.

(k) Earnings Statement. The Company will make generally available to its security holders and to the Representatives as soon as practicable an earnings statement (which need not be audited) covering a period of at least twelve months beginning with the first fiscal quarter of the Company commencing after the date of this Agreement that will satisfy the provisions of Section 11(a) of the Securities Act and the rules and regulations of the Commission thereunder.

(l) Continued Compliance with Securities Laws. The Company will comply with the Securities Act and the Exchange Act so as to permit the completion of the distribution of the Securities as contemplated by this Agreement, the Registration Statement, the Time of Sale Prospectus and the Prospectus. Without limiting the generality of the foregoing, the Company will, during the period when a prospectus relating to the Securities is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule), file on a timely basis with the Commission and Nasdaq all reports and documents required to be filed under the Exchange Act.

(m) Listing. The Company will use its best efforts to list, subject to notice of issuance, the Offered Shares and Warrant Shares on Nasdaq.

(n) Company to Provide Copy of the Prospectus in Form That May be Downloaded from the Internet. If requested by the Representatives, the Company shall cause to be prepared and delivered, at its expense, within the time period a Prospectus is required by the rules of the Commission to be filed, to the Representatives an “electronic Prospectus” to be used by the Underwriters in connection with the offering and sale of the Securities. As used herein, the term “electronic Prospectus” means a form of Prospectus, and any amendment or supplement thereto, that meets each of the following conditions: (i) it shall be encoded in an electronic format, satisfactory to the Representatives, that may be transmitted electronically by the Representatives and the other Underwriters to offerees and purchasers of the Securities; (ii) it shall disclose the same information as the paper Prospectus, except to the extent that graphic and image material cannot be disseminated electronically, in which case such graphic and image material shall be replaced in the electronic Prospectus with a fair and accurate narrative description or tabular representation of such material, as appropriate; and (iii) it shall be in or convertible into a paper format or an electronic format, satisfactory to the Representatives, that will allow investors to store and have continuously ready access to the Prospectus at any future time, without charge to investors (other than any fee charged for subscription to the Internet as a whole and for on-line time). The Company hereby confirms that it has included or will include in the Prospectus filed pursuant to EDGAR or otherwise with the Commission and in the Registration Statement at the time it was declared effective an undertaking that, upon receipt of a request by an investor or his or her representative, the Company shall transmit or cause to be transmitted promptly, without charge, a paper copy of the Prospectus.

(o) Agreement Not to Offer or Sell Additional Shares. During the period commencing on and including the date hereof and continuing through and including the 90th day following the date of the Prospectus (such period being referred to herein as the “Lock-up Period”), the Company will not, without the prior written consent of SVB Securities and Cowen (which consent may be withheld in their sole discretion), directly or indirectly: (i) sell, offer to sell, contract to sell or lend any Shares or Related Securities (as defined below); (ii) effect any short sale, or establish or increase any “put equivalent position” (as defined in Rule 16a-1(h) under the Exchange Act) or liquidate or decrease any “call

 

20


equivalent position” (as defined in Rule 16a-1(b) under the Exchange Act) of any Shares or Related Securities; (iii) pledge, hypothecate or grant any security interest in any Shares or Related Securities; (iv) in any other way transfer or dispose of any Shares or Related Securities; (v) enter into any swap, hedge or similar arrangement or agreement that transfers, in whole or in part, the economic risk of ownership of any Shares or Related Securities, regardless of whether any such transaction is to be settled in securities, in cash or otherwise; (vi) announce the offering of any Shares or Related Securities; (vii) file any registration statement under the Securities Act in respect of any Shares or Related Securities (other than as contemplated by this Agreement with respect to the Securities); (viii) effect a reverse stock split, recapitalization, share consolidation, reclassification or similar transaction affecting the outstanding Shares; or (ix) publicly announce the intention to do any of the foregoing; provided, however, that the Company may (A) effect the transactions contemplated hereby, (B) issue Shares or options to purchase Shares, or issue Shares upon exercise of options or warrants, pursuant to any stock option, warrants, stock bonus or other stock plan or arrangement described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, provided the recipients thereof provide to the Representatives a signed Lock-Up Agreement substantially in the form of Exhibit A hereto, (C) file a registration statement on Form S-8 with respect to any securities issued or issuable pursuant to any stock option, stock bonus or other stock plan or arrangement described in the Registration Statement, (D) assist any stockholder of the Company in the establishment of a trading plan by such stockholder pursuant to Rule 10b5-1 under the Exchange Act for the transfer of Shares; provided that such plan does not provide for the transfer of Shares during the Lock-up Period, and the establishment of such plan does not require or otherwise result in any public filing or other public announcement of such plan during such Lock-up Period and such plan is otherwise permitted to be implemented during the Lock-up Period pursuant to the terms of the lock-up agreement between such stockholder and the Underwriters in connection with the offering of the Securities, (E) issuanceof Shares upon exercise of the Pre-funded Warrants, (F) issue Shares in connection with the acquisition by the Company of the securities, business, property or other assets of another person or business entity or pursuant to any employee benefit plan assumed by the Company in connection with any such acquisition or (G) issue Shares, of restricted stock awards or of options to purchase Shares, in each case, in connection with joint ventures, commercial relationships (including lending relationships or any royalty or similar financing relationships) or other strategic transactions; provided that, in the case of immediately preceding clauses (F) and (G), the aggregate number of restricted stock awards and Shares issued in connection with, or issuable pursuant to the exercise of any options issued in connection with, all such acquisitions and other transactions does not exceed 5% of the aggregate number of Shares outstanding immediately following the offering of the Offered Shares pursuant to this Agreement. For purposes of the foregoing, “Related Securities” shall mean any options or warrants or other rights to acquire Shares or any securities exchangeable or exercisable for or convertible into Shares, or to acquire other securities or rights ultimately exchangeable or exercisable for, or convertible into, Shares.

(p) Future Reports to the Representatives. During the period of five years hereafter for so long as the Company is subject to the reporting requirements of the Exchange Act during that time, the Company will furnish to the Representatives, c/o SVB Securities LLC, 1301 Avenue of the Americas, 12th Floor, New York, NY 10019, Attention: Stuart R. Nayman: (i) after the end of each fiscal year, copies of the Annual Report of the Company containing the balance sheet of the Company as of the close of such fiscal year and statements of income, stockholders’ equity and cash flows for the year then ended and the opinion thereon of the Company’s independent public or certified public accountants; (ii) as soon as practicable after the filing or furnishing thereof, copies of each proxy statement, Annual Report on Form 10-K, Quarterly Report on Form 10-Q, Current Report on Form 8-K or other report filed or furnished by the Company with the Commission, FINRA or any securities exchange; and (iii) as soon as available, copies of any report or communication of the Company furnished or made available generally to holders of its capital stock; provided, however, that the requirements of this Section 3(q) shall be satisfied to the extent that such reports, statement, communications, financial statements or other documents are available on EDGAR.

 

21


(q) Investment Limitation. The Company shall not invest or otherwise use the proceeds received by the Company from its sale of the Securities in such a manner as would require the Company to register as an investment company under the Investment Company Act.

(r) No Stabilization or Manipulation; Compliance with Regulation M. The Company will not take, and will ensure that no affiliate or other person acting on behalf of the Company will take, directly or indirectly, without giving effect to activities by the Underwriters, any action designed to or that might reasonably be expected to cause or result in stabilization or manipulation of the price of the Shares or any reference security with respect to the Shares, whether to facilitate the sale or resale of the Offered Shares, the Warrant Shares or otherwise, , and the Company will, and shall cause each of its affiliates to, comply with all applicable provisions of Regulation M.

(s) Company to Provide Interim Financial Statements. Prior to the Closing Date, the Company will furnish the Underwriters, as soon as they have been prepared by or are available to the Company, a copy of any unaudited interim financial statements of the Company for any period subsequent to the period covered by the most recent financial statements appearing in the Registration Statement and the Prospectus.

(t) Emerging Growth Company Status. The Company will promptly notify the Representatives if the Company ceases to be an Emerging Growth Company at any time prior to the later of (i) the time when a prospectus relating to the Securities is not required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) and (ii) the expiration of the Lock-Up Period (as defined herein).

(u) Reservation of Warrant Shares. The Company shall, at all times while any Pre-Funded Warrants are outstanding, reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Shares, solely for the purpose of enabling it to issue Warrant Shares upon exercise of such Pre-funded Warrants, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of the then-outstanding Pre-funded Warrants.

(v) Amendments and Supplements to Permitted Rule 163B Communications. If at any time following the distribution of any Permitted Rule 163B Communication, there occurred or occurs an event or development as a result of which such Permitted Rule 163B Communication included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representatives and will promptly amend or supplement, at its own expense, such Permitted Rule 163B Communication to eliminate or correct such untrue statement or omission.

Section 4. Payment of Expenses. The Company agrees to pay all costs, fees and expenses incurred in connection with the performance of its obligations hereunder and in connection with the transactions contemplated hereby, including without limitation (i) all expenses incident to the issuance and delivery of the Securities (including all printing and engraving costs), (ii) all fees and expenses of the registrar and transfer agent of the Shares, (iii) all necessary issue, transfer and other stamp taxes in connection with the issuance and sale of the Securities to the Underwriters, (iv) all fees and expenses of the Company’s counsel, independent public or certified public accountants and other advisors, (v) all costs and expenses incurred in connection with the preparation, printing, filing, shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Time of Sale Prospectus, the Prospectus, each free writing prospectus prepared by or on behalf of, used by, or referred to by the Company, and each preliminary prospectus, each Permitted Rule 163B Communication, and all amendments and supplements thereto, and this Agreement, (vi) all filing

 

22


fees, reasonable and documented attorneys’ fees and expenses incurred by the Company or the Underwriters in connection with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any part of the Securities for offer and sale under the state securities or blue sky laws, and, if requested by the Representatives, preparing and printing a “Blue Sky Survey” or memorandum, and any supplements thereto, advising the Underwriters of such qualifications, registrations and exemptions, (vii) the costs, fees and expenses incurred by the Underwriters in connection with determining their compliance with the rules and regulations of FINRA related to the Underwriters’ participation in the offering and distribution of the Securities, including any related filing fees and the legal fees of, and disbursements by, counsel to the Underwriters, (viii) the costs and expenses of the Company relating to investor presentations on any “road show”, including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging expenses of the representatives, employees and officers of the Company and any such consultants, and 50% of the cost of any aircraft chartered in connection with the road show, with the other 50% being paid by the Underwriters, (ix) the fees and expenses associated with listing the Shares on Nasdaq, and (x) all other fees, costs and expenses of the nature referred to in Item 13 of Part II of the Registration Statement; provided that the fees and expenses of counsel with respect to clauses (vi) and (vii) above shall not exceed $40,000 in the aggregate. Except as provided in this Section 4 or in Section 7, Section 9 or Section 10 hereof, the Underwriters shall pay their own expenses, including the fees and disbursements of their counsel and their own travel and lodging expenses.

Section 5. Covenant of the Underwriters. Each Underwriter severally and not jointly covenants with the Company not to take any action that would result in the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of such Underwriter that otherwise would not, but for such actions, be required to be filed by the Company under Rule 433(d).

Section 6. Conditions of the Obligations of the Underwriters. The respective obligations of the several Underwriters hereunder to purchase and pay for the Securities as provided herein on the Closing Date shall be subject to the accuracy of the representations and warranties on the part of the Company set forth in Section 1 hereof as of the date hereof and as of the Closing Date as though then made to the timely performance by the Company of its covenants and other obligations hereunder, and to each of the following additional conditions:

(a) Comfort Letter. On the date hereof, the Representatives shall have received from RSM US LLP, independent registered public accountants for the Company, a letter dated the date hereof addressed to the Underwriters, in form and substance satisfactory to the Representatives, containing statements and information of the type ordinarily included in accountant’s “comfort letters” to underwriters, delivered according to Statement of Auditing Standards No. 72 (or any successor bulletin), with respect to the audited and unaudited financial statements and certain financial information contained in the Registration Statement, the Time of Sale Prospectus, and each free writing prospectus, if any.

(b) Compliance with Registration Requirements; No Stop Order; No Objection from FINRA. For the period from and after the date of this Agreement and through and including the Closing Date:

(i) The Company shall have filed the Prospectus with the Commission (including the information previously omitted from the Registration Statement pursuant to Rule 430B under the Securities Act) in the manner and within the time period required by Rule 424(b) under the Securities Act; or the Company shall have filed a post-effective amendment to the Registration Statement containing the information previously omitted from the Registration Statement pursuant to Rule 430B, and such post-effective amendment shall have become effective.

 

23


(ii) No stop order suspending the effectiveness of the Registration Statement or any post-effective amendment to the Registration Statement shall be in effect, and no proceedings for such purpose shall have been instituted or, to the knowledge of the Company, threatened by the Commission.

(iii) If a filing has been made with FINRA, FINRA shall have raised no objection to the fairness and reasonableness of the underwriting terms and arrangements.

(c) No Material Adverse Change. For the period from and after the date of this Agreement and through and including the Closing Date, in the judgment of the Representatives there shall not have occurred any Material Adverse Change.

(d) Opinion of Counsel for the Company. On the Closing Date, the Representatives shall have received the opinion of Latham & Watkins LLP, counsel for the Company, dated as of such date, in the form previously agreed to by, and reasonably satisfactory to, the Representatives, which opinion shall include opinions with respect to regulatory matters.

(e) Opinion of Intellectual Property Counsel for the Company. On the Closing Date, the Representatives shall have received the opinion of Goodwin Procter LLP, counsel for the Company with respect to intellectual property matters, dated as of such date, in the form previously agreed to by, and reasonably satisfactory to, the Representatives.

(f) Opinion of Counsel for the Underwriters. On the Closing Date, the Representatives shall have received the opinion of Goodwin Procter LLP, counsel for the Underwriters in connection with the offer and sale of the Securities, in form and substance satisfactory to the Underwriters, dated as of such date, with executed copies for each of the other Underwriters named on the Prospectus cover page.

(g) Officers Certificate. On the Closing Date, the Representatives shall have received a certificate executed by the Chief Executive Officer or President of the Company and the Senior Vice President, Finance of the Company, on behalf of the Company and not in their individual capacities, dated as of such date, to the effect set forth in Section 6(b)(ii) and further to the effect that:

(i) for the period from and including the date of this Agreement through and including such date, there has not occurred any Material Adverse Change;

(ii) the representations, warranties and covenants of the Company set forth in Section 1 of this Agreement are true and correct with the same force and effect as though expressly made on and as of such date; and

(iii) the Company has complied with all the agreements hereunder and satisfied all the conditions on its part to be performed or satisfied hereunder at or prior to such date.

(h) Bring-down Comfort Letter. On the Closing Date, the Representatives shall have received from RSM US LLP, independent registered public accountants for the Company, a letter dated such date, in form and substance satisfactory to the Representatives, which letter shall: (i) reaffirm the statements made in the letter furnished by them pursuant to Section 6(a), except that the specified date referred to therein for the carrying out of procedures shall be no more than three business days prior to the Closing Date; and (ii) cover certain financial information contained in the Prospectus.

 

24


(i) Lock-Up Agreements. On or prior to the date hereof, the Company shall have furnished to the Representatives an agreement in the form of Exhibit A hereto from each of the persons listed on Exhibit B hereto and from certain beneficial owners of the Company’s capital stock, as agreed upon by the Underwriters, and each such agreement shall be in full force and effect on each of the Closing Date.

(j) Rule 462(b) Registration Statement. In the event that a Rule 462(b) Registration Statement is filed in connection with the offering contemplated by this Agreement, such Rule 462(b) Registration Statement shall have been filed with the Commission on the date of this Agreement and shall have become effective automatically upon such filing.

(k) Additional Documents. On or before the Closing Date, the Representatives and counsel for the Underwriters shall have received such information, documents and opinions as they may reasonably request for the purposes of enabling them to pass upon the issuance and sale of the Securities as contemplated herein, or in order to evidence the accuracy of any of the representations and warranties, or the satisfaction of any of the conditions or agreements, herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the Securities as contemplated herein and in connection with the other transactions contemplated by this Agreement shall be satisfactory in form and substance to the Representatives and counsel for the Underwriters.

If any condition specified in this Section 6 is not satisfied when and as required to be satisfied, this Agreement may be terminated by the Representatives by notice from the Representatives to the Company at any time on or prior to the Closing Date, which termination shall be without liability on the part of any party to any other party, except that Section 4, Section 7, Section 9 and Section 10 shall at all times be effective and shall survive such termination.

Section 7. Reimbursement of Underwriters Expenses. If this Agreement is terminated by the Representatives pursuant to Section 6, Section 11 or Section 12, or if the sale to the Underwriters of the Securitieson the Closing Date is not consummated because of any refusal, inability or failure on the part of the Company to perform any agreement herein or to comply with any provision hereof, the Company agrees to reimburse the Representatives and the other Underwriters (or such Underwriters as have terminated this Agreement with respect to themselves), severally, upon demand for all out-of-pocket expenses that shall have been reasonably incurred by the Representatives and the Underwriters in connection with the proposed purchase and the offering and sale of the Securities, including, but not limited to, fees and disbursements of counsel, printing expenses, travel expenses, postage, facsimile and telephone charges.

Section 8. Effectiveness of this Agreement. This Agreement shall become effective upon the execution and delivery hereof by the parties hereto.

Section 9. Indemnification.

(a) Indemnification of the Underwriters. The Company agrees to indemnify and hold harmless each Underwriter, its affiliates, directors, officers, employees and agents, and each person, if any, who controls any Underwriter within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or expense, as incurred, to which such Underwriter or such affiliate, director, officer, employee, agent or controlling person may become subject, under the Securities Act, the Exchange Act, other federal or state statutory law or regulation, or the laws or regulations of foreign jurisdictions where Securities have been offered or sold or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of the Company), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (A) (i) any untrue statement or alleged untrue statement of a material fact contained in the

 

25


Registration Statement, or any amendment thereto, or the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading; or (ii) any untrue statement or alleged untrue statement of a material fact included in any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act, any Marketing Material, any Rule 163B Written Communication or the Prospectus (or any amendment or supplement to the foregoing), or the omission or alleged omission to state therein a material fact necessary in order to make the statements, in the light of the circumstances under which they were made, not misleading; or (B) the violation of any laws or regulations of foreign jurisdictions where Securities have been offered or sold; and to reimburse each Underwriter and each such affiliate, director, officer, employee, agent and controlling person for any and all reasonable and documented expenses (including the fees and disbursements of counsel) as such expenses are incurred by such Underwriter or such affiliate, director, officer, employee, agent or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action; provided, however, that the foregoing indemnity agreement shall not apply to any loss, claim, damage, liability or expense to the extent, but only to the extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company by the Representatives in writing expressly for use in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, any such free writing prospectus, any Marketing Material, any Rule 163B Written Communication or the Prospectus (or any amendment or supplement thereto), it being understood and agreed that the only such information consists of the information described in Section 9(b) below. The indemnity agreement set forth in this Section 9(a) shall be in addition to any liabilities that the Company may otherwise have.

(b) Indemnification of the Company, its Directors and Officers. Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, each of its directors, each of its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act, against any loss, claim, damage, liability or expense, as incurred, to which the Company, or any such director, officer or controlling person may become subject, under the Securities Act, the Exchange Act, or other federal or state statutory law or regulation, or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of such Underwriter), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, or any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading or (ii) any untrue statement or alleged untrue statement of a material fact included in any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus, that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433 of the Securities Act, any Rule 163B Written Communication or the Prospectus (or any such amendment or supplement) or the omission or alleged omission to state therein a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration Statement, such preliminary prospectus, the Time of Sale Prospectus, such free writing prospectus, such Rule 163B Written Communication or the Prospectus (or any such amendment or supplement), in reliance upon and in conformity with information relating to such Underwriter furnished to the Company by the Representatives in writing expressly for use therein; and to reimburse the Company, or any such director, officer or controlling person for any and all expenses (including the fees and disbursements of counsel) as such expenses are incurred by the Company, or any such director, officer or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action. The Company hereby acknowledges that the only information that the

 

26


Representatives have furnished to the Company expressly for use in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus that the Company has filed, or is required to file, pursuant to Rule 433(d) of the Securities Act, any Rule 163B Written Communication or the Prospectus (or any amendment or supplement to the foregoing) are the statements set forth in the first sentence of the fifth paragraph and the twelfth paragraph under the caption “Underwriting,” in the Preliminary Prospectus and the Prospectus. The indemnity agreement set forth in this Section 9(b) shall be in addition to any liabilities that each Underwriter may otherwise have.

(c) Notifications and Other Indemnification Procedures. Promptly after receipt by an indemnified party under this Section 9 of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying party under this Section 9, notify the indemnifying party in writing of the commencement thereof, but the omission so to notify the indemnifying party will not relieve the indemnifying party from any liability which it may have to any indemnified party to the extent the indemnifying party is not materially prejudiced as a proximate result of such failure and shall not in any event relieve the indemnifying party from any liability that it may have otherwise than on account of this indemnity agreement. In case any such action is brought against any indemnified party and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be entitled to participate in, and, to the extent that it shall elect, jointly with all other indemnifying parties similarly notified, by written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume the defense thereof with counsel reasonably satisfactory to such indemnified party; provided, however, that if the defendants in any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded that a conflict may arise between the positions of the indemnifying party and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it and/or other indemnified parties which are different from or additional to those available to the indemnifying party, the indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise participate in the defense of such action on behalf of such indemnified party or parties. Upon receipt of notice from the indemnifying party to such indemnified party of such indemnifying party’s election so to assume the defense of such action and approval by the indemnified party of counsel, such approval not to be unreasonably withheld or delayed, the indemnifying party will not be liable to such indemnified party under this Section 9 for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof unless (i) the indemnified party shall have employed separate counsel in accordance with the proviso to the preceding sentence (it being understood, however, that the indemnifying party shall not be liable for the fees and expenses of more than one separate counsel (together with one local counsel in each relevant jurisdiction), representing the indemnified parties who are parties to such action), which counsel (together with one local counsel in each relevant jurisdiction) for the indemnified parties shall be selected by the Representatives (in the case of counsel for the indemnified parties referred to in Section 9(a) above) or by the Company (in the case of counsel for the indemnified parties referred to in Section 9(b) above) or (ii) the indemnifying party shall not have employed counsel satisfactory to the indemnified party to represent the indemnified party within a reasonable time after notice of commencement of the action or (iii) the indemnifying party has authorized in writing the employment of counsel for the indemnified party at the expense of the indemnifying party, in each of which cases the fees and expenses of counsel shall be at the expense of the indemnifying party and shall be paid as they are incurred.

(d) Settlements. The indemnifying party under this Section 9 shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party against any loss, claim, damage, liability or expense by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated

 

27


by Section 9(c) hereof, the indemnifying party shall be liable for any settlement of any proceeding effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by such indemnifying party of the aforesaid request and (ii) such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened action, suit or proceeding in respect of which any indemnified party is or could have been a party and indemnity was or could have been sought hereunder by such indemnified party, unless such settlement, compromise or consent includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such action, suit or proceeding and does not include an admission of fault or culpability or a failure to act by or on behalf of such indemnified party.

Section 10. Contribution. If the indemnification provided for in Section 9 is for any reason held to be unavailable to or otherwise insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount paid or payable by such indemnified party, as incurred, as a result of any losses, claims, damages, liabilities or expenses referred to therein (i) in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters, on the other hand, from the offering of the Securities pursuant to this Agreement or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the Company, on the one hand, and the Underwriters, on the other hand, in connection with the statements or omissions which resulted in such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Underwriters, on the other hand, in connection with the offering of the Securities pursuant to this Agreement shall be deemed to be in the same respective proportions as the total proceeds from the offering of the Securities pursuant to this Agreement (before deducting expenses) received by the Company, and the total underwriting discounts and commissions received by the Underwriters, in each case as set forth on the front cover page of the Prospectus, bear to the aggregate initial public offering price of the Securities as set forth on such cover. The relative fault of the Company, on the one hand, and the Underwriters, on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company, on the one hand, or the Underwriters, on the other hand, and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.

The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be deemed to include, subject to the limitations set forth in Section 9(c), any documented legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending any action or claim. The provisions set forth in Section 9(c) with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this Section 10; provided, however, that no additional notice shall be required with respect to any action for which notice has been given under Section 9(c) for purposes of indemnification.

The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to this Section 10 were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to in this Section 10.

 

28


Notwithstanding the provisions of this Section 10, no Underwriter shall be required to contribute any amount in excess of the underwriting discounts and commissions received by such Underwriter in connection with the Securities underwritten by it and distributed to the public. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters’ obligations to contribute pursuant to this Section 10 are several, and not joint, in proportion to their respective underwriting commitments as set forth opposite their respective names on Schedule A. For purposes of this Section 10, each affiliate, director, officer, employee and agent of an Underwriter and each person, if any, who controls an Underwriter within the meaning of the Securities Act or the Exchange Act shall have the same rights to contribution as such Underwriter, and each director of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of the Securities Act and the Exchange Act shall have the same rights to contribution as the Company.

Section 11. Default of One or More of the Several Underwriters. If, on the Closing Date any one or more of the several Underwriters shall fail or refuse to purchase Securities that it or they have agreed to purchase hereunder on such date, and the aggregate number of Securities which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase does not exceed 10% of the aggregate number of the Securities to be purchased on such date, the Representatives may make arrangements satisfactory to the Company for the purchase of such Securities by other persons, including any of the Underwriters, but if no such arrangements are made by such date, the other Underwriters shall be obligated, severally and not jointly, in the proportions that the number of Securities set forth opposite their respective names on Schedule A bears to the aggregate number of Securities set forth opposite the names of all such non-defaulting Underwriters, or in such other proportions as may be specified by the Representatives with the consent of the non-defaulting Underwriters, to purchase the Securities which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase on such date. If, on the Closing Date, any one or more of the Underwriters shall fail or refuse to purchase Securities and the aggregate number of Securities with respect to which such default occurs exceeds 10% of the aggregate number of Securities to be purchased on such date, and arrangements satisfactory to the Representatives and the Company for the purchase of such Securities are not made within 48 hours after such default, this Agreement shall terminate without liability of any party to any other party except that the provisions of Section 4, Section 7, Section 9 and Section 10 shall at all times be effective and shall survive such termination. In any such case either the Representatives or the Company shall have the right to postpone the Closing Date, but in no event for longer than seven days in order that the required changes, if any, to the Registration Statement and the Prospectus or any other documents or arrangements may be effected.

As used in this Agreement, the term “Underwriter” shall be deemed to include any person substituted for a defaulting Underwriter under this Section 11. Any action taken under this Section 11 shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under this Agreement.

Section 12. Termination of this Agreement. Prior to the purchase of the Securities by the Underwriters on the Closing Date, this Agreement may be terminated by the Representatives by notice given to the Company if at any time: (i) trading or quotation in any of the Company’s securities shall have been suspended or limited by the Commission or by Nasdaq, or trading in securities generally on either Nasdaq or the NYSE shall have been suspended or limited, or minimum or maximum prices shall have been generally established on any of such stock exchanges; (ii) a general banking moratorium shall have been declared by any of federal, New York, or Massachusetts authorities; (iii) there shall have occurred any outbreak or escalation of national or international hostilities or any crisis or calamity, or any change in the United States or international financial markets, or any substantial change or development involving a prospective substantial change in United States’ or international political, financial or economic conditions, as in the judgment of the Representatives is material and adverse and makes it impracticable to market the Securities in the manner and on the terms described in the Time of Sale

 

29


Prospectus or the Prospectus or to enforce contracts for the sale of securities; (iv) in the judgment of the Representatives there shall have occurred any Material Adverse Change; or (v) the Company shall have sustained a loss by strike, fire, flood, earthquake, accident or other calamity of such character as in the judgment of the Representatives may interfere materially with the conduct of the business and operations of the Company regardless of whether or not such loss shall have been insured. Any termination pursuant to this Section 12 shall be without liability on the part of (a) the Company to any Underwriter, except that the Company shall be obligated to reimburse the expenses of the Representatives and the Underwriters pursuant to Section 4 or Section 7 hereof or (b) any Underwriter to the Company; provided, however, that the provisions of Section 9 and Section 10 shall at all times be effective and shall survive such termination.

Section 13. No Advisory or Fiduciary Relationship. The Company acknowledges and agrees that (a) the purchase and sale of the Securities pursuant to this Agreement, including the determination of the public offering price of the Securities and any related discounts and commissions, is an arm’s-length commercial transaction between the Company, on the one hand, and the several Underwriters, on the other hand, (b) in connection with the offering contemplated hereby and the process leading to such transaction, each Underwriter is and has been acting solely as a principal and is not the agent or fiduciary of the Company, or its stockholders, creditors, employees or any other party, (c) no Underwriter has assumed or will assume an advisory or fiduciary responsibility in favor of the Company with respect to the offering contemplated hereby or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company on other matters) and no Underwriter has any obligation to the Company with respect to the offering contemplated hereby except the obligations expressly set forth in this Agreement, (d) the Underwriters and their respective affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Company, and (e) the Underwriters have not provided any legal, accounting, regulatory or tax advice with respect to the offering contemplated hereby and the Company has consulted its own legal, accounting, regulatory and tax advisors to the extent it deemed appropriate.

Section 14. Representations and Indemnities to Survive Delivery. The respective indemnities, agreements, representations, warranties and other statements of the Company, of its officers and of the several Underwriters set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf of any Underwriter or the Company or any of its or their partners, officers or directors or any controlling person, as the case may be, and, anything herein to the contrary notwithstanding, will survive delivery of and payment for the Securities sold hereunder and any termination of this Agreement.

Section 15. Notices. All communications hereunder shall be in writing and shall be mailed, hand delivered or telecopied and confirmed to the parties hereto as follows:

 

If to the Representatives:       SVB Securities LLC
      1301 Avenue of the Americas, 12th Floor
                       New York, NY 10019
      Attention: Stuart R. Nayman
      Cowen and Company, LLC
      599 Lexington Avenue, 25th Floor
      New York, NY 10022
      Attention: Brad Friedman

 

30


with a copy to:       Goodwin Procter LLP
      The New York Times Building
      620 Eighth Avenue
      New York, New York 10018-1405
      Facsimile: (212) 355-3333
      Attention: Siavosh Salimi
If to the Company:       scPharmaceuticals Inc.
                   2400 District Avenue, Suite 310
      Burlington, Massachusetts 01803
      Facsimile: (857) 445-4834
      Attention: John Tucker
with a copy to:       Latham & Watkins LLP
      200 Clarendon Street
      Boston, MA 02216
      Facsimile: (617) 880-4541
      Attention: Peter Handrinos; Wesley Holmes

Any party hereto may change the address for receipt of communications by giving written notice to the others.

Section 16. Successors. This Agreement will inure to the benefit of and be binding upon the parties hereto, including any substitute Underwriters pursuant to Section 11 hereof, and to the benefit of the affiliates, directors, officers, employees, agents and controlling persons referred to in Section 9 and Section 10, and in each case their respective successors, and no other person will have any right or obligation hereunder. The term “successors” shall not include any purchaser of the Securities as such from any of the Underwriters merely by reason of such purchase.

Section 17. Partial Unenforceability. The invalidity or unenforceability of any section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other section, paragraph or provision hereof. If any section, paragraph or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable.

Section 18. Governing Law Provisions. This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York applicable to agreements made and to be performed in such state. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby (“Related Proceedings”) may be instituted in the federal courts of the United States of America located in the Borough of Manhattan in the City of New York or the courts of the State of New York in each case located in the Borough of Manhattan in the City of New York (collectively, the “Specified Courts”), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such court (a “Related Judgment”), as to which such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail to such party’s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum.

 

31


Section 19. General Provisions. This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This Agreement may be executed in two or more counterparts, each one of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein (express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit. The section headings herein are for the convenience of the parties only and shall not affect the construction or interpretation of this Agreement.

Section 20. Recognition of the U.S. Special Resolution Regimes.

(i) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States.

(ii) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.

As used in this Section 20:

“BHC Act Affiliate” has the meaning assigned to the term “affiliate” in, and shall be interpreted in accordance with, 12 U.S.C. § 1841(k).

“Covered Entity” means any of the following:

(i) a “covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b);

(ii) a “covered bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or

(iii) a “covered FSI” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b).

“Default Right” has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable.

“U.S. Special Resolution Regime” means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.

Each of the parties hereto acknowledges that it is a sophisticated business person who was adequately represented by counsel during negotiations regarding the provisions hereof, including, without limitation, the indemnification provisions of Section 9 and the contribution provisions of Section 10, and is fully informed regarding said provisions. Each of the parties hereto further acknowledges that the provisions of Section 9 and Section 10 hereof fairly allocate the risks in light of the ability of the parties to

 

32


investigate the Company, its affairs and its business in order to assure that adequate disclosure has been made in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, each free writing prospectus and the Prospectus (and any amendments and supplements to the foregoing), as contemplated by the Securities Act and the Exchange Act.

 

33


If the foregoing is in accordance with your understanding of our agreement, kindly sign and return to the Company the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms.

 

Very truly yours,
SCPHARMACEUTICALS INC.
By:  

/s/ John H. Tucker

  Name: John H. Tucker
  Title: Chief Executive Officer

 

34


The foregoing Underwriting Agreement is hereby confirmed and accepted by the Representatives in New York, New York as of the date first above written.

 

SVB SECURITIES LLC
COWEN AND COMPANY, LLC
Acting individually and as Representatives of the several Underwriters named in the attached Schedule A.
SVB SECURITIES LLC
By:  

/s/ Daniel B. Dubin

  Name: Daniel B. Dubin, M.D.
  Title: Vice Chairman, Global Co-Head of Investment Banking and Global Co-Head of Healthcare Investment Banking
COWEN AND COMPANY, LLC
By:  

/s/ E. James Streator, III

  Name: E. James Streator, III
  Title: Managing Director

 

35


Schedule A

 

Underwriters   

Number of

Offered Shares

to be Purchased

    

Number of Pre-

funded Warrants to
be Purchased

 

SVB Securities LLC

     2,979,000        1,307,250  

Cowen and Company, LLC

     2,979,000        1,307,250  

H.C. Wainwright & Co.

     529,600        232,400  

Maxim Group LLC

     132,400        58,100  
  

 

 

    

 

 

 

Total

     6,620,000        2,905,000  


Schedule B-1

Free Writing Prospectuses Included in the Time of Sale Prospectus

Free Writing Prospectus, filed with the Securities and Exchange Commission on November 22, 2022


Schedule B-2

 

1.

Public offering price: $5.25 per share and $5.249 per Pre-funded Warrant

 

2.

Number of Firm Shares: 6,620,000 shares; number of Pre-funded Warrants: 2,905,000

 

3.

Underwriting discount: 6.0%

 

4.

Exercise price per Pre-funded Warrant: $0.001


Schedule C

Permitted Rule 163B Communications

None.


Exhibit A

Form of Lock-up Agreement

____________________, 2022

SVB Securities LLC

Cowen and Company, LLC

As Representatives of the Several Underwriters

 

c/o

SVB Securities LLC

53 State Street, 40th Floor

Boston, MA 02109

and

Cowen and Company, LLC

599 Lexington Avenue

New York, NY 10022

 

RE:

scPharmaceuticals Inc. (the “Company”)

Ladies & Gentlemen:

The undersigned is an owner of shares of common stock, par value $0.0001 per share, of the Company (“Shares”) or of securities convertible into or exchangeable or exercisable for Shares. The Company proposes to conduct a public offering of Shares (the “Offering”) for which SVB Securities LLC and Cowen and Company, LLC (together with SVB Securities LLC, the “Representatives”) will act as the representatives of the underwriters. The undersigned recognizes that the Offering will benefit each of the Company and the undersigned. The undersigned acknowledges that the underwriters are relying on the representations and agreements of the undersigned contained in this letter agreement in conducting the Offering and, at a subsequent date, in entering into an underwriting agreement (the “Underwriting Agreement”) and other underwriting arrangements with the Company with respect to the Offering.

Annex A sets forth definitions for capitalized terms used in this letter agreement that are not defined in the body of this agreement. Those definitions are a part of this agreement.

In consideration of the foregoing, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned hereby agrees that, during the Lock-up Period, the undersigned will not (and will cause any Family Member not to), subject to the exceptions set forth in this letter agreement without the prior written consent of the Representatives, who may withhold their consent in their sole discretion:

 

   

Sell or Offer to Sell any Shares or Related Securities currently or hereafter owned either of record or beneficially (as defined in Rule 13d-3 under the Exchange Act) by the undersigned or such Family Member,

 

   

enter into any Swap,


   

make any demand for, or exercise any right with respect to, the registration under the Securities Act of the offer and sale of any Shares or Related Securities, or cause to be filed a registration statement, prospectus or prospectus supplement (or an amendment or supplement thereto) with respect to any such registration, or

 

   

publicly announce any intention to do any of the foregoing.

The foregoing will not apply to the registration of the offer and sale of the Shares, and the sale of the Shares to the underwriters, in each case as contemplated by the Underwriting Agreement. In addition, the foregoing restrictions shall not apply to (a) the transfer of Shares or Related Securities by gift, or by will or intestate succession to a Family Member or to a trust whose beneficiaries consist exclusively of one or more of the undersigned and/or a Family Member, (b) pursuant to a court order in respect of, or by operation of law as a result of, a divorce, or (c) if the undersigned is a non-individual, transfer of Shares or Related Securities to any affiliate (as such term is defined in Rule 405 of the Securities Act), limited partners, general partners, limited liability company members, trust beneficiaries or stockholders of the undersigned, or, if the undersigned is a corporation, to any wholly owned subsidiary of such corporation, if, in any such case, such transfer is not for value; provided, however, that in any such case, it shall be a condition to such transfer or disposition that:

 

   

each transferee executes and delivers to the Representatives an agreement in form and substance satisfactory to the Representatives stating that such transferee is receiving and holding such Shares and/or Related Securities subject to the provisions of this letter agreement and agrees not to Sell or Offer to Sell such Shares and/or Related Securities, engage in any Swap or engage in any other activities restricted under this letter agreement except in accordance with this letter agreement (as if such transferee had been an original signatory hereto); and

 

   

prior to the expiration of the Lock-up Period, no public disclosure or filing under the Exchange Act by any party to the transfer (donor, donee, transferor or transferee) shall be required, or made voluntarily, reporting a reduction in beneficial ownership of Shares in connection with such transfer.

Furthermore, notwithstanding the restrictions imposed by this letter agreement, the undersigned may (i) transfer Shares to the Company upon the exercise, net exercise or vesting of Related Securities during the Lock-up Period to cover tax withholding obligations in connection with such exercise, net exercise or vesting, or for the primary purpose of paying the exercise price of options or warrants to acquire Shares, in each case pursuant to a stock option, stock bonus or other equity incentive plan or arrangement or warrants existing as of the date hereof or described in the Prospectus (as defined in the Underwriting Agreement) and any Shares acquired upon such exercise, net exercise or vesting shall remain subject to this letter agreement, provided that if the undersigned is required to file a report under the Exchange Act related thereto, such report shall include a statement to the effect that the filing relates to the “net” or “cashless” exercise or vesting of such Related Securities, including, if applicable, the payment of taxes due as a result of such exercise, net exercise or vesting, (ii) establish a trading plan pursuant to Rule 10b5-1 of the Exchange Act, provided that no sales or other dispositions of Shares or Related Securities may occur under such plan during the Lock-up Period and no public announcement or filing under the Exchange Act regarding the establishment of such plan shall be required or made during the Lock-up Period, (iii) the transfer of the undersigned’s Shares or Related Securities pursuant to a sale of or an offer to purchase more than 50% of the voting stock of the Company, whether pursuant to a merger, tender offer or otherwise, to a third party or group of third parties, provided that in the event that such merger, tender offer or other transaction is not consummated, such Shares or Related Securities held by the undersigned shall remain subject to the restrictions on transfer set forth herein, (iv) transfer or dispose of Shares or Related Securities acquired in open market transactions after the completion of the Offering, or (v) transfer or dispose of

 

4


Shares or Related Securities acquired in the Offering; provided that in the case of (i) above, if the undersigned is required to make a filing under the Exchange Act reporting a reduction in beneficial ownership of Shares during the Lock-up Period, the undersigned shall include a statement describing the purpose of the transaction, provided further, that in the case of (iv) and (v) above, no filing under Section 16(a) of the Exchange Act shall be required or voluntarily made by the undersigned in connection with such transfer during the Lock-up Period.

The undersigned also agrees and consents to the entry of stop transfer instructions with the Company’s transfer agent and registrar against the transfer of Shares or Related Securities held by the undersigned and the undersigned’s Family Members, if any, except in compliance with the foregoing restrictions.

In the event that, during the Lock-up Period, the Representatives grant a discretionary release or waiver of Shares or Related Securities to (i) an officer or director of the Company or (ii) any stockholder of the Company who has executed and delivered to the Representatives a copy of this agreement and beneficially owns (as such term is defined in Rule 13d-3 under the Exchange Act) 5% or more of the outstanding Shares, calculated as of the closing of the Offering (each, a “Released Party”), then the Representatives shall be deemed to have also released or waived, on the same terms and conditions, if any, the prohibitions set forth in this agreement that would otherwise have applied to the undersigned on a pro-rata basis with respect to the same proportion (determined as a percentage) of the undersigned’s Shares or Related Securities as (x) the aggregate amount of Shares and Related Securities of the Released Party subject to the release or waiver bears to (y) the aggregate amount of shares of Shares and Related Securities held by the Released Party at the time of the release or waiver. The provisions of this paragraph will not apply: (i) unless and until the Representatives have first released or waived more than 1% of the Company’s total outstanding Shares (determined as of the closing date of the Offering for, and giving effect to, the Offering) in the aggregate from such prohibitions; (ii) (a) if the release or waiver is effected solely to permit a transfer not involving a disposition for value and (b) the transferee has agreed in writing to be bound by the same terms described in this agreement for the duration of the Lock-up Period; or (iii) if the release or waiver is granted to a holder of Shares or Related Securities in connection with an underwritten public offering, whether or not such offering is wholly or partially a secondary offering, of Shares pursuant to a registration statement under the Securities Act, provided, that in the event of any release or waiver pursuant to this clause (iii), the same percentage of the undersigned’s Shares or Related Securities (determined as set forth above) shall be released, but only for the purpose of participating in such public offering. In the event that, as a result of this paragraph, any Shares or Related Securities held by the undersigned are to be released or waived from the restrictions imposed by this agreement, the Representatives shall notify the Company two business days prior to the effective date of such release or waiver, and the Company, in turn, shall use commercially reasonable efforts notify the undersigned within one business day thereafter that the same percentage of aggregate Shares or Related Securities held by the undersigned has been released or waived from the restrictions set forth in this agreement; provided, that the failure to give any such notice to the Company or the undersigned shall not give rise to any claim or liability against the Underwriters, including the Representatives.

With respect to the Offering only, the undersigned waives any registration rights relating to registration under the Securities Act of the offer and sale of any Shares and/or any Related Securities owned either of record or beneficially by the undersigned, including any rights to receive notice of the Offering.

The undersigned confirms that the undersigned has not, and has no knowledge that any Family Member has, directly or indirectly, taken any action designed to or that might reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale of the Shares. The undersigned will not, and will cause any Family Member not to take, directly or indirectly, any such action.

 

5


Whether or not the Offering occurs as currently contemplated or at all depends on market conditions and other factors. The Offering will only be made pursuant to the Underwriting Agreement, the terms of which are subject to negotiation between the Company and the underwriters.

This letter agreement shall automatically terminate and be of no further effect upon the earliest to occur, if any, of (i) the Representatives, on the one hand, or the Company, on the other hand, advising the other party in writing, prior to the execution of the Underwriting Agreement, that it has determined not to proceed with the Offering, (ii) the termination of the Underwriting Agreement before the sale of Shares to the underwriters, and (iii) November 30, 2022, in the event that the Underwriting Agreement has not been executed by such date.

The undersigned hereby represents and warrants that the undersigned has full power, capacity and authority to enter into this letter agreement. This letter agreement is irrevocable and will be binding on the undersigned and the successors, heirs, personal representatives and assigns of the undersigned.

The undersigned acknowledges and agrees that none of the Underwriters has made any recommendation or provided any investment or other advice to the undersigned with respect to this letter agreement or the subject matter hereof, and the undersigned has consulted its own legal, accounting, financial, regulatory, tax and other advisors with respect to this letter agreement and the subject matter hereof to the extent the undersigned has deemed appropriate.

This letter agreement shall be governed by, and construed in accordance with, the laws of the State of New York.

 

6


 

Signature

 

Printed Name of Person Signing

(Indicate capacity of person signing if
signing as custodian or trustee, or on behalf
of an entity)

 

1


Annex A

Certain Defined Terms

Used in Lock-up Agreement

For purposes of the letter agreement to which this Annex A is attached and of which it is made a part:

 

   

Call Equivalent Position shall have the meaning set forth in Rule 16a-1(b) under the Exchange Act.

 

   

Exchange Act shall mean the Securities Exchange Act of 1934, as amended.

 

   

Family Member” shall mean the spouse of the undersigned, an immediate family member of the undersigned or an immediate family member of the undersigned’s spouse, in each case living in the undersigned’s household or whose principal residence is the undersigned’s household (regardless of whether such spouse or family member may at the time be living elsewhere due to educational activities, health care treatment, military service, temporary internship or employment or otherwise). “Immediate family member” as used above shall have the meaning set forth in Rule 16a-1(e) under the Exchange Act.

 

   

Lock-up Period” shall mean the period beginning on the date hereof and continuing through the close of trading on the date that is 90 days after the date of the Prospectus (as defined in the Underwriting Agreement).

 

   

Put Equivalent Position” shall have the meaning set forth in Rule 16a-1(h) under the Exchange Act.

 

   

Related Securities” shall mean any options or warrants or other rights to acquire Shares or any securities exchangeable or exercisable for or convertible into Shares, or to acquire other securities or rights ultimately exchangeable or exercisable for or convertible into Shares.

 

   

Securities Act” shall mean the Securities Act of 1933, as amended.

 

   

Sell or Offer to Sell” shall mean to:

 

   

sell, offer to sell, contract to sell or lend,

 

   

effect any short sale or establish or increase a Put Equivalent Position or liquidate or decrease any Call Equivalent Position

 

   

pledge, hypothecate or grant any security interest in, or

 

   

in any other way transfer or dispose of,

in each case whether effected directly or indirectly.

 

   

Swap” shall mean any swap, hedge or similar arrangement or agreement that transfers, in whole or in part, the economic risk of ownership of Shares or Related Securities, regardless of whether any such transaction is to be settled in securities, in cash or otherwise.

Capitalized terms not defined in this Annex A shall have the meanings given to them in the body of this lock-up agreement.

 

2


Exhibit B

Directors, Officers and Others

Signing Lock-up Agreement

Directors:

Mette Kirstine Agger

Minnie V. Baylor-Henry

William T. Abraham, M.D.    

Jack A. Khattar

Klaus Veitinger, M.D., Ph.D.

Frederick Hudson

Leonard D. Schaeffer

Sara Bonstein

Officers:

John Tucker

Rachael Nokes

Others:

Lundbeckfond Invest A/S

OrbiMed Private Investments VI, L.P.

5AM Co-Investors IV, L.P.

5AM Opportunities I, L.P.

5AM Ventures IV, L.P.

EX-4.1 3 d240360dex41.htm EX-4.1 EX-4.1

Exhibit 4.1

scPharmaceuticals Inc.

WARRANT TO PURCHASE SHARES OF COMMON STOCK

Number of Shares: [  ] (subject to adjustment)

 

Warrant No. [  ]    Original Issue Date: November 25, 2022

scPharmaceuticals Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [HOLDER] or its registered assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company up to a total of 2,905,000 shares of common stock, $0.0001 par value per share (“Common Stock”), of the Company (each such share, a “Warrant Share” and all such shares, the “Warrant Shares”) at an exercise price per share equal to $0.001 per share (as adjusted from time to time as provided in Section 9 herein, the “Exercise Price”) upon surrender of this Warrant to Purchase Shares of Common Stock (including any Warrants to Purchase Shares of Common Stock issued in exchange, transfer or replacement hereof, the “Warrant”) at any time and from time to time on or after the date hereof (the “Original Issue Date”) and, subject to the following terms and conditions:

1. Definitions. For purposes of this Warrant, the following terms shall have the following meanings:

(a) “Affiliate” means any Person directly or indirectly controlled by, controlling or under common control with, a Holder, as such terms are used in and construed under Rule 405 under the Securities Act, but only for so long as such control shall continue. For purposes of this definition, “control” (including, with correlative meanings, “controlled by,” “controlling” and “under common control with”) means, with respect to a Person, possession, direct or indirect, of (a) the power to direct or cause direction of the management and policies of such Person (whether through ownership of securities or partnership or other ownership interests, by contract or otherwise), or (b) at least 50% of the voting securities (whether directly or pursuant to any option, warrant, or other similar arrangement) or other comparable equity interests.

(b) “Commission” means the United States Securities and Exchange Commission.

(c) “Marketable Securities” means securities meeting all of the following requirements: (i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is then current in its filing of all required reports and other information under the Securities Act and the Exchange Act; (ii) the class and series of shares or other security of the issuer that would be received by Holder in connection with the Fundamental Transaction (as defined below) were Holder to exercise this Warrant on or prior to the closing thereof is then traded or quoted on a nationally recognized securities exchange, inter-dealer quotation system or over-the-counter market, and (iii) following the closing of such Fundamental Transaction, the Holder would not be restricted from publicly re-selling all of the issuer’s shares and/or other securities that would be received by the Holder in such Fundamental Transaction were the Holder to exercise or convert this Warrant in full on or prior to the closing of such Fundamental Transaction, except to the extent that any such restriction (x) arises solely under federal or state securities laws, rules or regulations, and (y) does not extend beyond six (6) months from the closing of such Fundamental Transaction.

(d) “Principal Trading Market” means the national securities exchange or other trading market on which the shares of Common Stock are primarily listed on and quoted for trading, which, as of the Original Issue Date, shall be the Nasdaq Global Select Market.

(e) “Registration Statement” means the Company’s Registration Statement on Form S-3 (File No. 333-254637), that became effective on April 29, 2021.

(f) “Securities Act” means the Securities Act of 1933, as amended.

 

1


(g) “Trading Day” means any weekday on which the Principal Trading Market is open for trading. If the shares of Common Stock are not listed or admitted for trading, “Trading Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in New York City are authorized or required by law or other governmental action to close.

(h) “Transfer Agent” means Computershare Trust Company, N.A, the Company’s transfer agent and registrar for the Common Stock, and any successor appointed in such capacity.

(i) “VWAP” means, for any date, the price determined by the first of the following clauses that applies: (i) if the Common Stock is then listed or quoted on a national securities exchange or other trading market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Principal Trading Market as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (ii) if the Common Stock is then listed or quoted for trading and neither OTCQB nor OTCQX is the Principal Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX, as applicable, (iii) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in the “Pink Sheets” published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (iv) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holder and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

2. Issuance of Securities; Registration of Warrants. The Warrant, as initially issued by the Company, is offered and sold pursuant to the Registration Statement. As of the Original Issue Date, the Warrant Shares are issuable under the Registration Statement. Accordingly, the Warrant and, assuming issuance pursuant to the Registration Statement or an exchange meeting the requirements of Section 3(a)(9) of the Exchange Act as in effect on the Original Issue Date, the Warrant Shares, are not “restricted securities” under Rule 144 promulgated under the Securities Act. The Company shall register ownership of this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant Register”), in the name of the record Holder (which shall include the initial Holder or, as the case may be, any assignee to which this Warrant is assigned hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

3. Registration of Transfers. Subject to compliance with all applicable securities laws, the Company shall, or will cause its Transfer Agent to, register the transfer of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all applicable transfer taxes (if any). Upon any such registration or transfer, a new warrant to purchase shares of Common Stock in substantially the form of this Warrant (any such new warrant, a “New Warrant”) evidencing the portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations in respect of the New Warrant that the Holder has in respect of this Warrant. The Company shall, or will cause its Transfer Agent to, prepare, issue and deliver at the Company’s own expense any New Warrant under this Section 3. Until due presentment for registration of transfer, the Company may treat the registered Holder hereof as the owner and holder for all purposes, and the Company shall not be affected by any notice to the contrary.

4. Exercise and Duration of Warrants.

(a) All or any part of this Warrant shall be exercisable by the registered Holder in the manner set forth in Section 10 at any time and from time to time on or after the Original Issue Date.

 

2


(b) The Holder may exercise this Warrant by delivering to the Company (i) an exercise notice, in the form attached as Schedule 1 hereto (the “Exercise Notice”), completed and duly signed, and (ii) payment of the Exercise Price for the number of Warrant Shares as to which this Warrant is being exercised (which may take the form of a “cashless exercise” if so indicated in the Exercise Notice pursuant to Section 10 below), and the date on which the last of such items is delivered to the Company (as determined in accordance with the notice provisions hereof) is an “Exercise Date.” The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares, if any. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

5. Delivery of Warrant Shares.

(a) Upon exercise of this Warrant, the Company shall promptly (but in no event later than three (3) Trading Days after the Exercise Date), upon the request of the Holder, credit such aggregate number of shares of Common Stock to which the Holder is entitled pursuant to such exercise to the Holder’s or its designee’s balance account with The Depository Trust Company (“DTC”) through its Deposit Withdrawal Agent Commission system, or if the Transfer Agent is not participating in the Fast Automated Securities Transfer Program (the “FAST Program”), issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the Company’s share register in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise. The Holder, or any natural person or legal entity (each, a “Person”) so designated by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date, irrespective of the date such Warrant Shares are credited to the Holder’s DTC account or the date of delivery of the certificates evidencing such Warrant Shares, as the case may be.

(b) If by the close of the third (3rd) Trading Day after the Exercise Date, the Company fails to deliver to the Holder a certificate representing the required number of Warrant Shares in the manner required pursuant to Section 5(a) or fails to credit the Holder’s DTC account for such number of Warrant Shares to which the Holder is entitled, and if after such third (3rd) Trading Day and prior to the receipt of such Warrant Shares, the Holder purchases (in an open market transaction, provided such purchases shall be made in a commercially reasonable manner at prevailing market prices) shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall, within two (2) Trading Days after the Holder’s request, in the Holder’s sole discretion, either (i) pay cash to the Holder in an amount equal to the Holder’s total purchase price (including commercially reasonable brokerage commissions, if any) for the shares of Common Stock so purchased, at which point the Company’s obligation to deliver such Warrant Shares shall terminate, or (ii) (A) pay in cash to the Holder the amount, if any, by which (1) the Holder’s total purchase price (including commercially reasonable brokerage commissions, if any) for the shares of Common Stock purchased in the Buy-In exceeds (2) the product of (x) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue, times (y) the price at which the sell order giving rise to such purchase obligation was executed (assuming such sale was executed on commercially reasonable terms at prevailing market prices and, if the sale was executed in multiple transactions, the volume weighted average price), and (B) at the option of the Holder, either (1) reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or (2) deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. The provisions of this Section 5(b) shall be the only remedy available to the Holder in the event the Company fails to deliver to the Holder the required number of Warrant Shares in the manner required pursuant to Section 5(a) and a Buy-In occurs. Irrespective of whether there is a Buy-In, no remedy shall be available, notwithstanding the requirements of Section 5(a), unless and until the Company fails to deliver to the Holder the required number of Warrant Shares by the close of the third Trading Day after the Exercise Date.

 

3


(c) To the extent permitted by law and subject to Section 5(b), the Company’s obligations to issue and deliver Warrant Shares in accordance with and subject to the terms hereof (including the limitations set forth in Section 11 below) are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in connection with the issuance of Warrant Shares. Subject to Section 5(b), nothing herein shall limit the Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver certificates representing shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

6. Charges, Taxes and Expenses. Issuance and delivery of certificates for shares of Common Stock upon exercise of this Warrant shall be made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding any applicable stamp duties) in respect of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company; provided, however, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration of any certificates for Warrant Shares or the Warrants in a name other than that of the Holder or an Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof.

7. Replacement of Warrant. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction (in such case) and, in each case, a customary and reasonable indemnity and surety bond, if requested by the Company. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other reasonable third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company’s obligation to issue the New Warrant.

8. Reservation of Warrant Shares. The Company covenants that it will, at all times while this Warrant is issued and outstanding, reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved shares of Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking into account the adjustments and restrictions of Section 9). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and non-assessable. The Company will take all such action as may be reasonably necessary to assure that such shares of Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the shares of Common Stock may be listed. The Company further covenants that it will not, without the prior written consent of the Holder, take any actions to increase the par value of the shares of Common Stock at any time while this Warrant is issued and outstanding.

9. Certain Adjustments. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment from time to time as set forth in this Section 9.

(a) Stock Dividends and Splits. If the Company, at any time while this Warrant is issued and outstanding, (i) pays a stock dividend on its shares of Common Stock or otherwise makes a distribution on any class of capital shares issued and outstanding on the Original Issue Date and in accordance with the terms of such stock on the Original Issue Date or as amended, as described in the Registration Statement, that is payable in shares of Common Stock,

 

4


(ii) subdivides its issued and outstanding shares of Common Stock into a larger number of shares of Common Stock, (iii) combines its issued and outstanding shares of Common Stock into a smaller number of shares of Common Stock or (iv) issues by reclassification of capital shares any additional shares of Common Stock of the Company, then in each such case the Exercise Price shall be multiplied by a fraction, the numerator of which shall be the number of shares of Common Stock issued and outstanding immediately before such event and the denominator of which shall be the number of shares of Common Stock issued and outstanding immediately after such event. Any adjustment made pursuant to clause (i) of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution, provided, however, that if such record date shall have been fixed and such dividend is not fully paid on the date fixed therefor, the Exercise Price shall be recomputed accordingly as of the close of business on such record date and thereafter the Exercise Price shall be adjusted pursuant to this paragraph as of the time of actual payment of such dividends. Any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become effective immediately after the effective date of such subdivision or combination.

(b) Pro Rata Distributions. If the Company, at any time while this Warrant is issued and outstanding, distributes to all holders of shares of Common Stock for no consideration (i) evidences of its indebtedness, (ii) any security (other than a distribution of shares of Common Stock covered by the preceding paragraph), (iii) rights or warrants to subscribe for or purchase any security, or (iv) cash or any other asset (in each case, “Distributed Property”), then, upon any exercise of this Warrant that occurs after the record date fixed for determination of stockholders entitled to receive such distribution, the Holder shall be entitled to receive, in addition to the Warrant Shares otherwise issuable upon such exercise (if applicable), the Distributed Property that such Holder would have been entitled to receive in respect of such number of Warrant Shares had the Holder been the record holder of such Warrant Shares immediately prior to such record date without regard to any limitation on exercise contained therein.

(c) Fundamental Transactions. If, at any time while this Warrant is issued and outstanding (i) the Company effects any merger or consolidation of the Company with or into another Person, in which the Company is not the surviving entity and in which the stockholders of the Company immediately prior to such merger or consolidation do not own, directly or indirectly, at least 50% of the voting power of the surviving entity immediately after such merger or consolidation, (ii) the Company effects any sale to another Person of all or substantially all of its assets in one transaction or a series of related transactions, (iii) pursuant to any tender offer or exchange offer (whether by the Company or another Person), holders of capital stock tender shares representing more than 50% of the voting power of the capital stock of the Company and the Company or such other Person, as applicable, accepts such tender for payment, (iv) the Company consummates a share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than the 50% of the voting power of the capital stock of the Company (except for any such transaction in which the stockholders of the Company immediately prior to such transaction maintain, in substantially the same proportions, the voting power of such Person immediately after the transaction) or (v) the Company effects any reclassification of the shares of Common Stock or any compulsory share exchange pursuant to which the shares of Common Stock are effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock covered by Section 9(a) above) (in any such case, a “Fundamental Transaction”), then following such Fundamental Transaction the Holder shall have the right to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant without regard to any limitations on exercise contained herein (the “Alternate Consideration”). The Company shall not effect any Fundamental Transaction in which the Company is not the surviving entity or the Alternate Consideration includes securities of another Person unless (i) the Alternate Consideration is solely cash and the Company provides for the simultaneous “cashless exercise” of this Warrant pursuant to Section 10 below or (ii) prior to, simultaneously with or promptly following the consummation thereof, any successor to the Company, surviving entity or other Person (including any purchaser of assets of the Company) shall assume the obligation to deliver to the Holder such Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be

 

5


entitled to receive, and the other obligations under this Warrant. The provisions of this paragraph (c) shall similarly apply to subsequent transactions analogous of a Fundamental Transaction type. Notwithstanding the foregoing, in the event of a Fundamental Transaction where the consideration payable to holders of shares of Common Stock consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities, then this Warrant shall automatically be deemed to be exercised in full in a “cashless exercise” pursuant to Section 10 below effective immediately prior to and contingent upon the consummation of such Fundamental Transaction.

(d) Number of Warrant Shares. Simultaneously with any adjustment to the Exercise Price pursuant to Section 9 (including any adjustment to the Exercise Price that would have been effected but for the final sentence in this paragraph (d)), the number of Warrant Shares that may be purchased upon exercise of this Warrant shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the increased or decreased number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior to such adjustment. Notwithstanding the foregoing, in no event may the Exercise Price be adjusted below the par value of the shares of Common Stock then in effect.

(e) Calculations. All calculations under this Section 9 shall be made to the nearest one-millionth of one cent or the nearest share, as applicable.

(f) Notice of Adjustments. Upon the occurrence of each adjustment pursuant to this Section 9, the Company at its expense will, at the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the Company’s transfer agent.

(g) Notice of Corporate Events. If, while this Warrant is issued and outstanding, the Company (i) declares a dividend or any other distribution of cash, securities or other property in respect of its shares of Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital stock of the Company or any subsidiary, (ii) authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii) authorizes the voluntary dissolution, liquidation or winding up of the affairs of the Company, then, except if such notice and the contents thereof shall be deemed to constitute material non-public information, the Company shall deliver to the Holder a notice of such transaction at least ten (10) days prior to the applicable record or effective date on which a Person would need to hold shares of Common Stock in order to participate in or vote with respect to such transaction; provided, however, that the failure to deliver such notice or any defect therein shall not affect the validity of the corporate action required to be described in such notice. In addition, if while this Warrant is issued and outstanding, the Company authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction contemplated by Section 9(c), other than a Fundamental Transaction under clause (iii) of Section 9(c), then, except if such notice and the contents thereof shall be deemed to constitute material non-public information, the Company shall deliver to the Holder a notice of such Fundamental Transaction at least ten (10) days prior to the date such Fundamental Transaction is consummated.

10. Payment of Cashless Exercise Price. Notwithstanding anything contained herein to the contrary, the Holder may, in its sole discretion, satisfy its obligation to pay the Exercise Price through a “ cashless exercise”, in which event the Company shall issue to the Holder the number of Warrant Shares in an exchange of securities effected pursuant to Section 3(a)(9) of the Securities Act as determined as follows:

X = Y [(A-B)/A]

where:

“X” equals the number of Warrant Shares to be issued to the Holder;

 

6


“Y” equals the total number of Warrant Shares with respect to which this Warrant is then being exercised;

“A” equals the last VWAP immediately preceding the time of delivery of the Exercise Notice giving rise to the applicable “cashless exercise”, as set forth in the applicable Exercise Notice (to clarify, the “last VWAP” will be the last VWAP as calculated over an entire Trading Day such that, in the event that this Warrant is exercised at a time that the Trading Market is open, the prior Trading Day’s VWAP shall be used in this calculation); and

“B” equals the Exercise Price per Warrant Share then in effect on the Exercise Date.

For purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and acknowledged that the Warrant Shares issued in such a “cashless exercise” transaction shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally issued (provided that the Commission continues to take the position that such treatment is proper at the time of such exercise).

Except as set forth in Section 12 (payment of cash in lieu of fractional shares), in no event will the exercise of this Warrant be settled in cash.

11. Limitations on Exercise.

(a) Notwithstanding anything to the contrary contained herein, the Company shall not effect any exercise of this Warrant, and the Holder shall not be entitled to exercise this Warrant for a number of Warrant Shares in excess of that number of Warrant Shares which, upon giving effect or immediately prior to such exercise, would result in (i) the aggregate number of shares of Common Stock beneficially owned by the Holder, its Affiliates and any other Persons whose beneficial ownership of shares of Common Stock would be aggregated with the Holder’s for purposes of Section 13(d) of the Exchange Act (such as any other members of a Section 13(d) “group”) exceeding 4.99% (the “Maximum Percentage”) of the total number of issued and outstanding shares of Common Stock of the Company following such exercise, or (ii) the combined voting power of the securities of the Company beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of shares of Common Stock would be aggregated with the Holder’s for purposes of Section 13(d) of the Exchange Act (such as any other members of a Section 13(d) “group”) exceeding 4.99% of the combined voting power of all of the securities of the Company then outstanding following such exercise. For purposes of this Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x) the Company’s most recent Form 10-Q or Form 10-K, as the case may be, filed with the Commission prior to the date hereof, (y) a more recent public announcement by the Company or (z) any other notice by the Company or its transfer agent setting forth the number of shares of Common Stock outstanding. Upon the written request of the Holder, the Company shall within three (3) Trading Days confirm in writing or by electronic mail to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder since the date as of which such number of outstanding shares of Common Stock was reported. By written notice to the Company, the Holder may from time to time increase or decrease the Maximum Percentage to any other percentage specified not in excess of 19.99% specified in such notice; provided that any such increase will not be effective until the sixty-first (61st) day after such notice is delivered to the Company. For purposes of this Section 11(a), the aggregate number of shares of Common Stock or voting securities beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of shares of Common Stock would be aggregated with the Holder’s for purposes of Section 13(d) of the Exchange Act (such as any other members of a Section 13(d) “group”) shall include the shares of Common Stock issuable upon the exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (x) exercise of the remaining unexercised and non-cancelled portion of this Warrant by the Holder and (y) exercise or conversion of the unexercised, non-converted or non-cancelled portion of any other securities of the Company that do not have voting power (including without limitation any securities of the Company which would entitle the holder thereof to acquire at any time shares of Common Stock, including without limitation any debt,

 

7


preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, shares of Common Stock), is subject to a limitation on conversion or exercise analogous to the limitation contained herein and is beneficially owned by the Holder or any of its Affiliates and other Persons whose beneficial ownership of shares of Common Stock would be aggregated with the Holder’s for purposes of Section 13(d) of the Exchange Act (such as any other members of a Section 13(d) “group”).

(b) This Section 11 shall not restrict the number of shares of Common Stock which a Holder may receive or beneficially own in order to determine the amount of securities or other consideration that such Holder may receive in the event of a Fundamental Transaction as contemplated in Section 9(c) of this Warrant.

12. No Fractional Shares. No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of any fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole number and the Company shall pay the Holder in cash the fair market value (based on the last VWAP immediately preceding the time of delivery of the applicable Exercise Notice) for any such fractional shares.

13. Notices. Any and all notices or other communications or deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via confirmed e-mail prior to 5:30 P.M., New York City time, on a Trading Day, (ii) the next Trading Day after the date of transmission, if such notice or communication is delivered via confirmed e-mail on a day that is not a Trading Day or later than 5:30 P.M., New York City time, on any Trading Day, (iii) the Trading Day following the date of mailing, if sent by nationally recognized overnight courier service specifying next business day delivery, or (iv) upon actual receipt by the Person to whom such notice is required to be given, if by hand delivery. The addresses and e-mail addresses for such communications shall be:

If to the Company:

scPharmaceuticals Inc.

2400 District Ave. Suite 310

Burlington, MA 01803

Attn: Rachael Nokes, Senior Vice President – Finance

Tel.: ***************

Email: ***************

With copies to:

Attn: John Tucker

Email: ***************

and

Latham & Watkins LLP

200 Clarendon Street

Boston, MA 02116

Attn: Peter Handrinos

Email: peter.handrinos@lw.com

If to the Holder, to its address or e-mail address set forth herein or on the books and records of the Company.

 

8


Or, in each of the above instances, to such other address or e-mail address as the recipient party has specified by written notice given to each other party at least five (5) days prior to the effectiveness of such change.

14. Warrant Agent. The Company shall initially serve as warrant agent under this Warrant. Upon ten (10) days’ notice to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or stockholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder’s last address as shown on the Warrant Register.

15. Miscellaneous.

(a) No Rights as a Stockholder. The Holder, solely in such Person’s capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of capital stock of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person’s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company.

(b) Authorized Shares. Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, amalgamation, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and non-assessable Warrant Shares upon the exercise of this Warrant, and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform its obligations under this Warrant.

(c) Successors and Assigns. Subject to compliance with applicable securities laws, this Warrant may be assigned by the Holder. This Warrant may not be assigned by the Company without the written consent of the Holder, except to a successor in the event of a Fundamental Transaction in which this Warrant is not automatically “cashless exercised”. This Warrant shall be binding on and inure to the benefit of the Company and the Holder and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors and assigns.

(d) Amendment and Waiver. Except as otherwise provided herein, this Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.

(e) Acceptance. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained herein.

(f) Governing Law; Jurisdiction. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY,

 

9


ENFORCEMENT AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY.

(g) Headings. The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of the provisions hereof.

(h) Severability. In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the Holder will attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

10


IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its authorized officer as of the date first indicated above.

 

SCPHARMACEUTICALS INC.
By:  

 

  Name:
  Title:

 

11


SCHEDULE 1

FORM OF EXERCISE NOTICE

[To be executed by the Holder to purchase shares of Common Stock under the Warrant]

Ladies and Gentlemen:

(1) The undersigned is the Holder of Warrant No. ___ (the “Warrant”) issued by scPharmaceuticals Inc., a Delaware corporation (the “Company”). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in the Warrant.

(2) The undersigned hereby exercises its right to purchase ___________ Warrant Shares pursuant to the Warrant.

(3) The Holder intends that payment of the Exercise Price shall be made as (check one):

 

 

Cash Exercise

 

 

“Cashless Exercise” under Section 10 of the Warrant

(4) Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in accordance with the terms of the Warrant. The Warrant Shares shall be delivered to the following DWAC Account Number:

(5) By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under Section 11(a) of the Warrant to which this notice relates.

 

Dated:  

 

Name of

Holder:

 

 

By:  

 

Name:  

 

Title:  

 

(Signature must conform in all respects to name of Holder as specified on the face of the Warrant)

 

12

EX-5.1 4 d240360dex51.htm EX-5.1 EX-5.1

Exhibit 5.1

 

  200 Clarendon Street
  Boston, Massachusetts 02116
  Tel: +1.617.948.6000 Fax: +1.617.948.6001
  www.lw.com
  FIRM / AFFILIATE OFFICES
LOGO   Austin    Milan
  Beijing    Munich
  Boston    New York
  Brussels    Orange County
  Century City    Paris
November 23, 2022   Chicago    Riyadh
  Dubai    San Diego
  Düsseldorf    San Francisco
  Frankfurt    Seoul
  Hamburg    Shanghai
  Hong Kong    Silicon Valley
  Houston    Singapore
  London    Tel Aviv
  Los Angeles    Tokyo
  Madrid    Washington, D.C

scPharmaceuticals Inc.

2400 District Avenue, Suite 310

Burlington, MA 01830

Re: Registration Statement on Form S-3; 9,525,000 shares of Common Stock, $0.0001 par value per share and pre-funded warrant to purchase 2,905,000 shares of Common Stock

To the addressee set forth above:

We have acted as special counsel to scPharmaceuticals Inc., a Delaware corporation (the “Company”), in connection with the proposed issuance of 6,620,000 shares of common stock (the “Shares”), $0.0001 par value per share (the “Common Stock”), and a pre-funded warrant to purchase 2,905,000 shares of Common Stock (the “Pre-funded Warrant”). The Shares and the Pre-funded Warrant are included in a registration statement on Form S-3 under the Securities Act of 1933, as amended (the “Act”), filed with the Securities and Exchange Commission (the “Commission”) on March 23, 2021 (as amended, the “Registration Statement”), and are being offered pursuant to a base prospectus dated April 29, 2021 (the “Base Prospectus”) and a prospectus supplement dated November 21, 2022 filed with the Commission pursuant to Rule 424(b) under the Act (together with the Base Prospectus, the “Prospectus”). The Shares and the Pre-funded Warrant are being sold pursuant to an underwriting agreement dated November 22, 2022 between the Company and SVB Securities LLC and Cowen and Company, LLC, as representatives of the several underwriters named in Schedule A thereto (the “Underwriting Agreement”). This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or the Prospectus, other than as expressly stated herein with respect to the issue of the Shares, the Pre-funded Warrant and the Warrant Shares (as defined below).

As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware (the “DGCL”), and we express no opinion with respect to any other laws.


November 23, 2022

Page 2

 

LOGO

 

Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof:

1. When the Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers, and have been issued by the Company against payment therefor (not less than par value) in the circumstances contemplated by the Underwriting Agreement, the issue and sale of the Shares will have been duly authorized by all necessary corporate action of the Company and the Shares will be validly issued, fully paid and nonassessable.

2. When the Pre-funded Warrant shall have been duly issued by the Company against payment therefor in the circumstances contemplated by Underwriting Agreement, the issue and sale of the Pre-funded Warrant will have been duly authorized by all necessary corporate action of the Company, and the Pre-funded Warrant will be the legally valid and binding obligation of the Company, enforceable against the Company in accordance with its terms.

3. When the shares of Common Stock initially issuable upon exercise of the Pre-funded Warrant (the “Warrant Shares”) shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the Pre-funded Warrant holders, and have been issued by the Company against payment therefor (not less than par value) in the circumstances contemplated by the Pre-funded Warrant, the issue of the Warrant Shares will have been duly authorized by all necessary corporate action of the Company and the Warrant Shares will be validly issued, fully paid and nonassessable.

In rendering the foregoing opinions, we have assumed that (i) the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL and (ii) upon the issue of any of the Warrant Shares, the total number of shares of Common Stock issued and outstanding will not exceed the total number of shares of Common Stock that the Company is then authorized to issue under its Amended and Restated Certificate of Incorporation and by the board of directors of the Company in connection with the offering contemplated by the Registration Statement and the Prospectus.

With your consent, we have assumed that the status of the Pre-funded Warrant as legally valid and binding obligations of the Company is not affected by any (i) breaches of, or defaults under, agreements or instruments, (ii) violations of statutes, rules, regulations or court or governmental orders, or (iii) failures to obtain required consents, approvals or authorizations from, or make required registrations, declarations or filings with, governmental authorities.

Our opinions are subject to: (i) the effect of bankruptcy, insolvency, reorganization, preference, fraudulent transfer, moratorium or other similar laws relating to or affecting the rights and remedies of creditors; (ii) (a) the effect of general principles of equity, whether considered in a proceeding in equity or at law (including the possible unavailability of specific performance or injunctive relief), (b) concepts of materiality, reasonableness, good faith and fair dealing, and (c) the discretion of the court before which a proceeding is brought; and (iii) the invalidity under certain circumstances under law or court decisions of provisions providing for the indemnification of or contribution to a party with respect to a liability where such indemnification or contribution is contrary to public policy. We express no opinion as to (a) any provision for liquidated damages, default interest, late charges, monetary penalties, make-whole


November 23, 2022

Page 3

 

LOGO

 

premiums or other economic remedies to the extent such provisions are deemed to constitute a penalty; (b) consents to, or restrictions upon, governing law, jurisdiction, venue, arbitration, remedies, or judicial relief; (c) any provision requiring the payment of attorneys’ fees, where such payment is contrary to law or public policy; (d) other applicable exceptions; and (e) the severability, if invalid, of provisions to the foregoing effect.

This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Company’s Current Report on Form 8-K dated November 23, 2022 and to the reference to our firm in the Prospectus under the heading “Legal Matters.” In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.

 

Sincerely,
/s/ LATHAM & WATKINS LLP
EX-101.SCH 5 scph-20221122.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 6 scph-20221122_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 7 scph-20221122_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 8 g240360dsp65.jpg GRAPHIC begin 644 g240360dsp65.jpg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g240360dsp66.jpg GRAPHIC begin 644 g240360dsp66.jpg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end XML 10 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information
Nov. 22, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001604950
Document Type 8-K
Document Period End Date Nov. 22, 2022
Entity Registrant Name scPharmaceuticals Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-38293
Entity Tax Identification Number 46-5184075
Entity Address, Address Line One 2400 District Avenue
Entity Address, Address Line Two Suite 310
Entity Address, City or Town Burlington
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01803
City Area Code (617)
Local Phone Number 517-0730
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common stock, par value $0.0001
Trading Symbol SCPH
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period true
XML 11 d240360d8k_htm.xml IDEA: XBRL DOCUMENT 0001604950 2022-11-22 2022-11-22 false 0001604950 8-K 2022-11-22 scPharmaceuticals Inc. DE 001-38293 46-5184075 2400 District Avenue Suite 310 Burlington MA 01803 (617) 517-0730 false false false false Common stock, par value $0.0001 SCPH NASDAQ true true EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.scpharmaceuticals.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d240360d8k.htm d240360dex11.htm d240360dex41.htm d240360dex51.htm scph-20221122.xsd scph-20221122_lab.xml scph-20221122_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d240360d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d240360d8k.htm" ] }, "labelLink": { "local": [ "scph-20221122_lab.xml" ] }, "presentationLink": { "local": [ "scph-20221122_pre.xml" ] }, "schema": { "local": [ "scph-20221122.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "scph", "nsuri": "http://www.scpharmaceuticals.com/20221122", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d240360d8k.htm", "contextRef": "duration_2022-11-22_to_2022-11-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.scpharmaceuticals.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d240360d8k.htm", "contextRef": "duration_2022-11-22_to_2022-11-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.scpharmaceuticals.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.scpharmaceuticals.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.scpharmaceuticals.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.scpharmaceuticals.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.scpharmaceuticals.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.scpharmaceuticals.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.scpharmaceuticals.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.scpharmaceuticals.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.scpharmaceuticals.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.scpharmaceuticals.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.scpharmaceuticals.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.scpharmaceuticals.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.scpharmaceuticals.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.scpharmaceuticals.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.scpharmaceuticals.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.scpharmaceuticals.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.scpharmaceuticals.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.scpharmaceuticals.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.scpharmaceuticals.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.scpharmaceuticals.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.scpharmaceuticals.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.scpharmaceuticals.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.scpharmaceuticals.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.scpharmaceuticals.com//20221122/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 18 0001193125-22-292028-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-292028-xbrl.zip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Ǿ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